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Recent development of a variety of superparamagnetic and ferromagnetic iron/iron oxide 
(Fe/Fe3O4) nanoparticles with different surface chemistry have been widely studied for numerous 
biological applications such as drug delivery, as diagnostics, hyperthermia and magnetic 
resonance imaging. The wide applications of Fe/Fe3O4 nanoparticles are possible since they 
exhibit favorable properties as high magnetization ability, are smaller than 100 nm in size, they 
can be coated with several ligands which allow drug delivery at a specific site and are 
biocompatible. By using Fe/Fe3O4 nanoparticles as drug delivery agents treatment costs and side 
effects can be reduced, however treatment efficacy can be increased. We have demonstrated that 
Fe/Fe3O4 nanoparticles can be utilized in different methods depending on their properties, to be 
used as therapeutic agents for cancer treatment. In one method we have taken advantage of the 
Fe/Fe3O4 nanoparticles magnetic ability to produce hyperthermia (heat) in cancer cells when 
subjected to an alternative magnetic field. Here we use the cell based delivery system since the 
size of the nanoparticles are small they can be taken up by monocyte/ macrophage like cells for 
systemic transportation to the inflamed cancer cite. The hyperthermia study was conducted in 
mice with pancreatic cancer. This study demonstrated that the life expectancy of the mice 
increased by 31%. In the next method we took the advantage of the surface chemistry of the 
Fe/Fe3O4 nanoparticles and changed it with dopamine-peptide and dopamine-thiosemicarbazone 
ligands. The advantage of the peptide is to deliver the nanoparticle to its target site and the 
thiosemicarbazone analogue is used as an iron chelator that would initiate apoptosis in cancer 
cells. This nanoplatform was tested in 4T1 breast cancer cell line and normal fibroblast cell line 
and demonstrated that it was effective towards the cancer cell line than the normal cell line at a 
ratio of 5:1 of thiosemicarbazone analogue : dopamine on the nanoparticle. However further 
studies are needed to be done to clarify the effectiveness of this nanosystem. 
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Chapter 1 - Antitumor Activity by Combination of Iron Chelators  
with Peptide Sequences 
1.1 Abstract 
In the past few years, the use of iron chelators and therapeutic peptide sequences has been 
studied for the treatment of cancer. Recent studies have shown that the iron chelators that belong 
to the thiosemicarbazone group show antitumor activity in the nanomolecular range. Their ability 
to inhibit tumor growth is understood based on several factors: 
1) Tumor cells proliferate much faster than normal cells, therefore they need enhanced Fe 
concentrations for cell growth.  
2) Several enzymes that are needed to catalyze the synthesis of DNA require Fe. Without fast 
DNA synthesis, the high proliferation rates of virtually all cancers cannot be maintained. 
As a tumor proliferates, blood vessels grow with it through angiogenesis. Therefore, 
inhibition of angiogenesis is a therapeutic strategy that can be used to inhibit tumor growth. We 
have assembled a nanoplatform for tumor treatment.  A thiosemicarbazone analogue and a 
peptide sequence are attached onto a Fe/Fe3O4 nanoparticle. The peptide sequence 
CGKRK(D[KLAKLAKKLAKLAK])PLFAERL comprises of 26 amino acid residues and 
contains two important sequences, which are the CGKRK peptide, which provides tumor homing 
ability and D[KLAKLAK]2, which disrupts the mitochondrial cell walls and initiates cell death 
(apoptosis). The nanoparticle can enhance apoptosis by using hyperthermia.  Fe/Fe3O4 
nanoparticles can also be used for imaging purposes (MRI). Therefore, by combining various 
therapeutic methods, we can produce a synergistic approach to treat tumors. The efficacy of the 
nanoplatform has been tested on 4T1 breast cancer cell line and its IC50 values have been 
calculated. Most importantly, the nanoplatform has been optimized to show significantly lower 
IC50 values against 4T1 breast cancer cells than against healthy murine fibroblast cells. This 
approach has the potential of leading to a new generation of nanoplatforms for cancer treatment 





 Cancer has become one of the leading causes of death worldwide. The most major cause 
of cancer death in woman is breast cancer.
1
 It is said that in a woman’s lifetime there is a 1 in 7 
in risk of developing breast cancer.
2
 
Even though there are several treatment methods for breast cancer such as hormone therapy, 
aromatase inhibitors and cytotoxins, there is still improvement needed in specifically targeting 
cancer cells to reduce side effects and toxicity in normal cells.
2
 For successful cancer treatment it 
is essential to deliver chemotherapeutic agents in effective dose into tumor cells minimizing 
adverse effects into normal healthy cells.
3
 
 Cancer cells have different growth characteristics than normal cells. In order to supply 
nutrients for the excessive growth of the cells, leaky blood vessels are formed, due to the absence 
of pericytes lining the endothelial cells. These blood vessels have pore sizes of 100-600nm, 
which can be of advantage, allowing nanoparticles to diffuse into tumor cells. Therefore, 
chemotherapeutic agents coupled onto nanoparticles can be used as successful drug carriers into 
tumor cells, increasing drug tumor accumulation.
3
 
 Other than leaky pores on the blood vessels they also express specific endothelial 
markers, which are not prominent in normal cells. Ligands such as peptides can bind to these 
vascular markers and when these ligands are bound to drugs they can be concentrated in tumor 
cells increasing efficacy and reducing adverse effects to normal cells.
3,4
 
 Peptides play an important role in living organisms. Protein–protein interactions are 
important in many biological processes such as cell division, to programmed cell death and are 
also important in regulating these biological processes.
5
 
 Mimicking these protein-protein interactions can be used as a therapeutic strategy to 
specifically target and destroy cancer cells.
5
 
 In our study we have taken advantage of this concept and used two peptide sequences 
where one is the CGKRK which homes the blood vessels in tumors but not vessels of normal 
tissues. The other is D[KLAKLAK]2 pro-apototic sequence which disrupts membranes that are of 




 Our main goal is to inhibit the growth of tumors by inhibiting the growth of blood 




advantage of using peptides is that they can be conjugated easily together with other compounds. 
Therefore by conjugating these two peptides together and attaching them onto the surface of an 
iron/iron oxide (Fe/Fe3O4) nanoparticle we can home the tumors and increase the binding 
efficiency to the target and lead the cell towards apoptosis.
4
 
 We have also incorporated an iron chelator onto the Fe/Fe3O4 nanoparticle. Iron is an 
important element for several cellular processes which are proliferation, DNA synthesis 
mitochondrial electron transport and is also essential for the activity of iron requiring enzymes 
such as ribonucleotide reductase which is important for DNA synthesis and repair.
6,7
 
 The iron chelator that we have used belongs to the thiosemicarbazone group. The 
mechanism of action by which this thiosemicarbazone analogue would deliver its activity is via 
several pathways;  
1. Since cancer cells have an increased requirement of iron for the rapid proliferation, by 
using iron chelators we can deprive the cell from iron, thus inhibiting cell 
proliferation.  
2. By chelating iron we can inhibit the activity of ribonucleotide reductase enzyme and 
inhibit DNA synthesis and repair. 
3. Since these chelators form iron complexes that redox cycle they can generate reactive 
oxygen species (ROS) such as hydroxyl radicals which induce DNA oxidation and 
mitochondrial damage leading the cells towards apotosis.
6,7
 
 In our research we have combined the use of tumor homing and pro-apoptotic peptide 
sequences with iron chelators, which we assume would produce a synergistic effect in cancer 
treatment. 
 Here we have assembled a multifunctional Fe/Fe3O4 nanosystem, where the CGKRK 
peptide will carry the nanoparticle to the tumor vascular cells and into their mitochondria. The 
D[KLAKLAK]2 sequence will disrupt the mitochondria leading the cell towards apoptosis. The 
thiosemicarbazone analogue will enhance the cell towards apoptosis by chelating the iron in 
cancer cells. The Fe/Fe3O4 nanoparticle can be used as a carrier or produce apoptosis via 
hyperthermia and it can also be used as a diagnostic for MRI (magnetic resonance imaging). 
 The activity of this nanosystem was tested in 4T1 breast cancer cell line and was 
compared with normal murine fibroblast cell line. The thiosemicarbazone iron chelator and 




size of the nanoparticles were in good range for therapeutic use. From the cell culture tests it was 
determined that the nanosystem containing the 5:1 (thiosemicarbazone analogue: dopamine) ratio 
is a good system to use for therapeutic use since it showed a difference in cell toxicity in 4T1 
breast cancer cell line than the fibroblast normal cell line. 
1.3 Literature and Reviews 
1.3.1 Cancer Statistics 
Currently, cancer is the second major cause of death in USA, shortly behind heart 
disease. The number of deaths from cancer in 2012 is estimated to 577,150.
1
 Although, as Figure 
1.1 indicates, the combined cancer death rates in the US are on a slight decline, mortality from 
cancer during the 2010’s is approximately the same than during the 1950’s. A more detailed look 
at cancer mortality by gender in the US from 1975 to 2008 reveals that men have a 16% higher 





Figure 1.1:-  Cancer death rates by gender in USA from 1975 to 2008. 





 In our research we would be focusing on treating breast cancer, because breast cancer is 
the most widespread type of cancer in women (Figure 1.2). Only skin cancer is, statistically 
speaking, almost as important. Breast cancer has the highest incidence rate in the US. Early stage 





Stage 1 breast cancers are two centimeters or less in size, no spread has 
been observed. Stage 2A breast cancer has a diameter of up to two centimeters with no lymph 
node involvement.  Stage 2B has lymph node involvement. Metastatic breast cancer results from 
spreading to the lymph nodes. Stage 3A breast cancer (locally advanced breast cancer) has 
spread to lymph nodes under the arm, or 4-9 axillary lymph nodes. 
 
Stage 3B breast cancer is a 
tumor of any size that has spread to the skin, chest wall, or internal mammary lymph nodes 
(located beneath the breast and inside the chest). Stage 3C breast cancer is a tumor of any size 
that has spread to more than 10 axillary lymph nodes. Final stage is Stage 4 breast cancer. It is 
defined as a tumor, regardless of size, that has spread to places far away from the breast, such as 
bones, lungs, liver, brain, or distant lymph nodes. The 5-year relative survival is at 98 percent for 
stage 1, 83.6 percent at stage 2, and 23.4 percent at stage 3. This clearly indicates that new 
treatment methods for later stages in breast cancer have to be developed. Since these cases are 
highly metastatic, they are usually non-operable. Therefore, nanoplatforms have to be developed 
that are able to target tumors and metastases alike. They should cause apoptosis (programmed 
cell death) rather than necrosis, because the latter results in massive inflammation.
10
 
Figure 1.2:- Cancer incidence rates among women in USA from 1975 to 2008 






Peptides are synthesized by amino acids as their building blocks. They are a short 
sequence containing less than 50 amino acid monomers attached to each other by peptide bonds 
which is formed through a condensation reaction (Figure 1.3).
11 
 
Figure 1.3:- Peptide bond formation through a condensation reaction. 
  
 Recently, scientists in various fields such as chemistry, biochemistry, physiology and 
pharmacology have shown interest in peptides.
12 
 Peptides are important due to their biological functions as hormones, enzyme inhibitors, 
substrates, neurotransmitters and immunomodulators. When bound to their targets, they are able 
to trigger cell-cell communication, control metabolism, immune defense, sensitivity to pain and 
electrolyte levels. Therefore, scientists are interested in designing and developing new peptides 
and study their physiological effects as therapeutic agents.
12 
 
1.4.1 Building Blocks of Peptides 
 There are 20 standard α- amino acids (Figure 1.4) that can be used to synthesize peptides. 
They are abbreviated either by a 3 letter or one letter method (Table 1.1). The one letter 


























Table 1.1:- Standard amino acids  
 
Amino acid Three letter code One letter code Side chain 
Hydrophobic Aliphatic Side Chains 
Glycine Gly G H- 
Alanine Ala A CH3- 
Valine Val V (CH3)2CH- 
Leucine Leu L (CH3)2CHCH2- 
Isoleucine Ile I CH3CH2(CH3)CH- 









Hydrophilic Uncharged Side Chains 
Serine Ser S OH-CH2- 
Threonine Thr T CH3-CH(OH)- 
Cysteine Cys C HS-CH2- 
Asparagine Asn N H2NOC-CH2- 
Glutamine Gln Q H2NOC-CH2CH2- 
Hydrophilic Charged Side Chains 
Lysine Lys K H2N-CH2CH2CH2CH2- 
Aspartic acid Asp D HOOC-CH2- 




























Aromatic Side Chains 
















 These α-amino acids differ from each other by their side chains (Figure 1.4). They are 
divided into hydrophobic aliphatic, hydrophilic uncharged, hydrophilic charged and aromatic 
groups according to the chemical nature of their side chains (Table 1.1).
11
 
 Most peptides are synthesized using the L-isomer but the D-isomer can also be used. 
However they will be toxic since they cannot be degraded by proteolytic enzymes. 
1.4.2  Cell-Penetrating Peptides 
 In the last 10 years Cell-penetrating peptides (CPPs) have opened a new research field 
due to the finding of the ability of these short peptides to rapidly translocate through plasma 
membranes in a nonreceptor mediated manner.
11, 13, 14
 
 It is still a major drawback that drugs cannot translocate cellular membranes and access 
their intra cellular targets.
13, 15
 
 There are several types of CPPs: protein transduction domains (PTDs), Trojan peptides, 
or membrane translocating sequences (MTS), are used for peptide-mediated delivery of bio 
active molecules. In many examples, the results that were obtained when delivering by means of 
CPPs were superior to other methods, such as electroporation.
15
 Membranes of eukaryotic cells 
have a barrier that only allows certain substances into the cell and restricts hydrophilic drugs into 
the cell. The conventional intracellular processes such as transport proteins (carrier proteins, 
pumps and gated ion channels) regulate the intake of substances through the plasma membrane. 









source, which can be saturated. Therefore, limiting the delivery capacity since the number of 
carriers are fixed in a cell.
13, 14, 15
 
 New nonphysiological methods such as electroporation and liposomes have been studied 
and used for gene drug delivery. However, these methods are found to be only effective in vitro 
and are restricted in in vivo effectiveness due to toxicity, cell damage lack of tissue and cell 
specificity. CPPs have appeared to possess rapid translocation in both in vitro and in vivo of 
various cargos such as oligonucleotides, peptides, plasmids, liposomes and nanoparticles. 
Therefore development of CPPs, provide a noninvasive delivery method of hydrophilic and 
genetic material which can be used as a successful drug delivery method.
11, 13, 14
 
 This field first emerged with the discovery of the viral protein TAT, translocating through 
cellular membranes into the cell by Green et al. in 1988.
16
 Later in 1994 Alain Prochiantz group 
discovered a 14 amino acid peptide penetration, which had DNA recognition ability and was able 
to translocate the whole protein into the cell. Since then hundreds of CPPs have been identified 
and studied for their therapeutical importance.
11, 15, 17 
1.4.2.1  Cell-Penetrating Peptide Features and Classification  
 A clear classification of CPPs has not been defined yet. The general features that they 
present are that they are up to 30 amino acids or less in length and have a net positive charge due 
to the high content of basic amino acids and are amphipathic in nature.
13, 18
 
 CPPs can be classified into three classes;
13
 
1. Protein derived CPPs 
They contain the minimal effective partial sequence of the parent translocation protein. 
E.g. Penetratin, TAT, pVEC 
2. Model CPPs 
These sequences are designed by mimicking structures of known CPPs or aimed to 
produce amphipathic α-helical structures. 
E.g. Model amphipathic peptides (MAP) , (Arg)7 
3. Designed CPPs 
They are chimeric peptides where hydrophilic and hydrophobic parts are coupled from 
different origin. 




 Examples of CPPs are shown in Table 1.2. The above-mentioned CPPs have vastly 
expanded into numerous analogues.
11 
 In our research we have incorporated the use of MAP (D(KLAKLAK)2 sequence) peptide 
where it is also used as a pro-apoptotic peptide other than a CPP. Its pro-apoptotic activity will 
be explained in detail later in this chapter. 
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Protein derived CPP 
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immunodeficiency 
virus 1  
(amino acids 48-60) 
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Peptide derived from 
fusion sequence of 
HIV-1 gp41 protein 
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Minimal active part 
of galanin (amino 
acids 1-12) coupled 
to mastoparan via 
Lys 
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1.4.2.2  Mechanism of Membrane Translocation of CPPs 
 Studies on the uptake of CPPs showed that the translocation mechanism was not affected 





C, confirming a non-endocytotic pathway of translocation and an energy independent 
pathway.
 
Chemical modifications such as retro-, enantio (D isomer) or retroenantio- analogs of 
the peptide sequences also did not affect the internalization of CPPs. These findings suggests that 
CPPs translocation occurs through the plasma lipid bilayer of the cell membrane.
15, 18,19
 
 Many studies have been conducted to postulate a defined mechanism of CPPs 
translocation, however it is hard to define a particular method since there are various 
mechanisms that have been suggested. 
 One method that was suggested was the formation of the inverted micelle model. 
According to this method the positively charged peptide interact with the negatively charged 
plasma membrane, next invagination of the peptide takes place with the aid of hydrophobic 
amino acids forming the inverted micelle. (Figure 1.5).
15, 18, 19 
 Recent studies show that an energy dependent process takes place such as extracellular 
heparane sulfate and various endocytosis pathways such as macropinocytosis, clathrin- 




















 When CPPs are not attached to any cargo they translocate into cells by the different 
endocytosis pathways mentioned above. In higher concentrations they can translocate through 
rapidly by direct penetration. However when CPPs are conjugated to a cargo the endocytotic 
translocation is prominent (Figure 1.6).
11, 15
 
 Since it is not clear which pathway peptide mediated membrane translocation takes place, 
it may occur simultaneously through several different pathways. The process may also depend on 
the differences in the biophysical properties of the peptide and their cargo.
15 
 
Figure 1.6:- Cellular CPP uptake mechanisms.
11 
A. Endocytotic pathway with combination of macropinocytosis (1), clathrin (2), and 
caveolin (3) dependent endocytosis. Can occur at low or high CPP concentration. 
B. Direct penetration (4) of CPPs at high concentration. 




1.4.3 Targeting Cancer Cells and Angiogenic Blood Vasculature 
 In order to deliver the payload successfully to the cancer site it is important to 
specifically target the site. Most anticancer drugs cannot discriminate between normal and cancer 
tissues. Therefore it is important to use a targeting drug delivery technique to enhance the drug 




 Tumor cell survival mainly depends on the growth of new blood vessels known as 
angiogenesis. These newly formed blood vessels provide nutrients and oxygen necessary for the 
development of cancers. Therefore by inhibiting tumor vasculature using peptides, the blood 
supply to tumors will be restricted and inhibiting tumor progression.
20 
 Cancer cells have different growth characteristics compared to normal cells. Cancer 
blood vessels express different endothelial surface markers (receptors) which are not expressed 
in normal vessels or expressed at a lower level.
2,3, 21, 22
 
 The usage of peptides that recognize these cancer vasculature markers can be used as 
promising agents to deliver drugs to cancer sites.
20
 
These peptides have unique characteristics such as;
20 
− High tissue penetrating ability due to small molecular weight (average ≤ 50 amino 
acids) 
− Low immunogenicity 
− High affinity towards target 
− Good stability 
− Rarely producing drug resistance 
− Easily synthesized and can be conjugated with other agents 
 In our research we used the peptide sequence CGKRK as the tumor homing sequence. 
This peptide sequence was identified by screening phage peptide libraries, when used to screen 
for peptides that home epidermal tumors in mice. This peptide sequence specifically recognized 
tumor vessels but not normal tissue vessels. This peptide sequence specifically recognized tumor 
vesscular endothelial cells and tumor cells but not normal tissue vessels. A sulfated 
polysaccharide heparan sulfate is the receptor for CGKRK peptide. This receptor is mainly 




CGKRK peptide attached nanoplatform can be internalized into the cell through heparin sulfate 




1.4.3.1  Peptide Screening 
 Peptide screening is done by using the phage display method, which was introduced by       
G. Smith in 1985.
 




 A phage library can produce up to 10
10
 different peptides and proteins that can be used 
for different functions. This can also be used to determine protein- ligand interactions, receptor 
and antibody binding sites.
26
 
 Phages are viruses consisting of a single- stranded DNA enclosed in a protein coat that 
infects gram-negative bacteria. The DNA sequence of interest is inserted into the genome of the 
filamentous bacteriophage. The protein or peptide that was encoded by the DNA sequence is 
then expressed on the surface of the filamentous phage. This is a good method to study billions 
of diverse peptides that can be made simultaneously, rather than genetically engineering proteins 
or peptides individually and studying them separately.
26, 27
 
 This filamentous phage, is amplified by transfecting into Escherichia coli, and are grown 
in culture media and the phage particles can be purified. These phage particles which have 
specific proteins and peptides exposed on its surface, can next be screened by affinity binding to 
either an antibody or receptor (Figure 1.7).
27, 28
 
 Identification of important peptides can also be done by in vivo phage peptide screening, 
which was studied by Ruoslahti in 1996. Here a live animal is used as the target. This method is 







 Figure 1.7:- Screening for specific peptides from peptide phage libraries. 
 The peptide that specifically binds to the target among 10
10
 different peptides that are 






1.4.4 Pro-apoptotic Peptide Sequence 
 Pro-apototic peptides were originally designed as synthetic antibacterial peptides. They 
can be either cationic, α-helical or amphipathic in nature. These peptides can disrupt negatively 
charged membranes by attraction of their cationic amino acids, with the anionic groups of the 
phospholipids. The electrostatic binding of these peptides disrupt the phospholipid membrane. 
These peptides are not toxic to eukaryotic cells however prokaryotic membranes and 
mitochondrial membranes (since they have been originated from bacteria) can be disrupted. This 
is mainly due to the fact that both prokaryotic and mitochondrial membranes have a higher 




 Delivering drugs to subcellular organelles such as the nucleus and mitochondria can 
cause irreversible damage to these organelles leading to cell death. This can be used as a more 
direct and effective therapeutic method to kill cancer cells and inhibit their growth.
31
 
 The mitochondria are important organelles in the cell since they control many functions 
such as regulating calcium, redox signaling and most importantly apoptosis. Therefore apoptosis 
can be induced in cancer cells by disrupting the mitochondrial membrane. Once the 
mitochondrial membrane is disrupted it releases caspase activating proteins such as cytochrome 
c. Caspases are responsible for the cascade of reactions involved in apoptosis.
31, 32
 
 In our research we have used the α-helical amphipathic peptide D[KLAKLAK]2 as the 
pro-apoptotic peptide sequence. This peptide sequence is synthesized by using the D- enentiomer 
amino acids and is repeated D(KLAKLAKKLAKLAK). The advantage of using the D-
enantiomer is to avoid protease degradation and enhance efficacy.
4, 30, 33 
   
 Therefore by conjugating the homing peptide sequence and pro-apototic peptide sequence 
we can improve therapeutic efficacy and lower the toxicity in normal cells and cancer treatment 






1.4.5 Peptide Clevage Sequence 
Proteases are proteolytic enzymes that cleave proteins at specific sites. Cleavage of 
proteins is performed to process or degrade proteins in synthesis and maturation of cells or for 
modifiying the protein for signal transduction. Proteases are important for regulating various 
biological porcessors. Identifying protease subsrate is important to understand the interaction 
between the enzyme and the protein. Many screening studies have been done by proteomic 
methods to identify the protein substrates.
34, 35
 
In our research, we have incorporated one of these clevage sequences to facilitate the 
cleavage of the peptide sequence for its activity. The cleavage sequence we have incorporated is 
PLFAERL sequence, which is cleaved by the calpain enzyme, which is overexpressed in cancer 
cells. Calpains are Ca
2+
 dependent cytosolic cysteine proteases that catalyze limited proteolytic 
activity of target proteins. The physiological role of calpains is that they regulate cellular 
functions by cleaving various cytoskeletal proteins for cell mobility and cell cycle progression. 
It has been found that calpain cleaves the PLFAERL sequence at the phenylalanin and alanine 
bond site, which would release the peptide sequence from the nanoparticle (as shown in Figure 





Figure 1.8:- Clevage of CGKRK(D[KLAKLAKKLAKLAK])PLFAERL peptide sequence from 





1.4.6 Peptide Synthesis 
 Introducing synthetic methods to synthesize peptide was essential since the conventional 
biological synthetic methods such as phage display methods were time consuming and tedious. 
Biological methods had several disadvantages involving extreme conditions that could destroy 
the phage particles and it was not possible to produce the D- enantio form of the peptides, non-
coded peptides or cyclic peptides.
27
 
 Before the introduction of amino- protecting groups by Emil Fischer in 1903 was 
successful in coupling two amino acids.
38
 However this method was not suitable for producing 
longer peptides and it was hard to isolate and purify the desired peptide since numerous 
variations of the peptide could be formed (Table 1.3) when carried out in solution. Which lead to 
the finding of solid phase peptide synthesis (SPPS) method, which was pioneered by Bruce 
Merrifield in the early 1960s.
39, 40, 41
 
 SPPS involves numerous repetitive steps including N deprotection, amino acid coupling, 
washing and filtration steps. The advantages of using SPPS are that the coupling reactions can be 
performed more rapidly and to completion without any other variation of the peptide           
(Table 1.3), by using excess amount of activated amino acids which can be easily separated from 
the growing peptide during the washing and filtration steps.
40, 41
 
 Nowadays peptides that range from 30-50 amino acids per peptide can be synthesized 





















1.4.6.1 Solid Phase Peptide Synthesis 
 Matrix polymers are used as the solid support for SPPS. These are often referred to as 
resins. They are crosslinked polystyrene beads ranging from 100-400 µm in diameter. They have 
a loading capacity of 0.5-0.8 mmol/g if all the linker sites were accessible. In order to access the 
buried linker sites the resin should be swelled in DCM (Dichloromethane) and DMF                
(N, N-dimethylformamide) prior to chemically attaching an amino acid. They contain a linker 
which allows the anchoring of the N protected C-terminal amino acid moiety (Figure 1.9) to the 
resin through an ester or amide bond.
41
 
 There are several different types of resins depending on their linker molecules        
(Figure 1.10); peptide amides such as Rink amide resin, Pal resin, Sieber resin. Peptide acids, 




hydroxymethyl- based resins such as Wang resin, Sasrin resin and HMPB resin. And trityl resins 
as trityl chloride resin and 2-chlorotrityl chloride resin.
41 
 Most of these resins have the first C terminal N-protected amino acids preloaded onto the 
resin and are commercially available. This is done to avoid the difficult and hazardous methods 
in linking the first amino acid to the linker for some resins.
40, 41
 
Figure 1.9:- Fmoc protected α- amino C-terminal amino acid. 

































X = H, Wang resin
X = OMe, Sasrin resin
HMPB resin
X= H, Trityl chloride resin




1.4.7 Principles of SPPS 
 SPPS is performed in a glass tube like vessel (Figure 1.11), which has a frit to filter off 
the solutions by suction filtration. Since the resin beads are fragile mechanical stirring such as 
magnetic stirring is not preferred. It is necessary to agitate the reaction mixture smoothly to 
allow the coupling reactions to occur. Here smooth agitation can be performed by rocking, 




Figure 1.11:- Solid phase peptide synthesis reaction vessel.
41 
 
 The peptide sequence is synthesized from the C-terminus to the N-terminus where the 
synthesis starts from the opposite direction that the peptide sequence is written in.
41
 
 The amino acids have protecting groups to avoid side reactions from occurring and to 
produce the desired peptide sequence accurately. There are two types of protecting groups, 
which are the temporary protecting groups that protect the α-amino group. This protecting group 
can be easily removed under mild basic conditions. The Fmoc (9-Fluorenylmethyloxycarbonyl) 
protecting group is an example for this category of protecting groups. The other type of 
protecting group is the side chain protecting groups such as Trt (Trityl), Pbf (2,2,4,6,7-
Pentamethyldihydrobenzofuran-5-sulfonyl), Boc (tert-Butyloxycarbonyl ) and tBu (tert-Butyl). 
These groups should be stable during the peptide elongation reaction conditions. These 
protecting groups are removed in the final step when cleaving the peptide sequence from the 








 When coupling an amino acid to the currently synthesizing peptide, an excess of 2-10 
times the concentration of amino acid is used compared to the resin. This ensures that the amino 
acids will attach to all the active sites.
41
 
1.4.7.1 Solid Phase Peptide synthesis Protocol 
 There are many methods to synthesize peptides. In this section the protocol used to 
synthesize the peptides in our research is described (Figure 1.12).
41 
1. Transfer the amino acid preloaded dry resin into the glass tube. 
2. Add DCM into the glass tube to immerse the resin and swirl for 20 min. 
3. Remove the DCM by filtration under vacuum. 
4. Add DMF into glass tube swirl for 1 min. 
5. Remove DMF by filtration under vacuum. 
6. Prepare the coupling solution by dissolving 1:3 ratio of resin to amino acid and 1:2.9 ratio 
of resin to HBTU (O-benzotriazol-1-yl-N,N,N,N -tetramethyluronium 
hexafluorophosphate) is dissolved in 23:1 ration of DMF: DIEA (N,N-
Diisopropylethylamine) coupling solution. 
7. Add the coupling solution into the glass tube and swirl for 30 min. 
8. Remove coupling solution by filtration under vacuum. 
9. Repeat steps 6, 7 and 8. 
10. Wash resin 4 times with DMF swirl for 30s each and filter solution each time. 
11. Add 20% piperidne in DMF solution to deprotect the Fmoc protected α- amino group 
swirl for 1 min and filter solution by vacuum. 
12. Again add 20% piperidne in DMF solution and swirl for 10 min and filter solution by 
vacuum. 
13. Wash resin 5 times with DMF swirl for 30s each and filter solution each time. 
14. Repeat steps 6 to 13 until desired peptide sequence is synthesized. 
15. Cleave peptide sequence from resin and side chain protecting groups by adding cleavage 
cocktail of TFA: TIPS (Triisopropyl silane): water at a ratio of 95:2.5:2.5 per 100mg of 
resin. 
16. Swirl for 3 hrs. 
17. Filter peptide solution into cold ether (Peptide will precipitate in cold ether). 




19. Add cold ether vortex to wash peptide and centrifuge. 
20. Centrifuge and decant ether. 
21. Repeat steps 19 and 20. 
22. Dry precipitated peptide under argon and store in -200C freezer for later use. 
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1.4.8 Peptide Purification and Characterization 
 A peptide that has been synthesized by SPPS should be purified and isolate from 
impurities prior to characterization. High performance liquid chromatography (HPLC) is the 
ideal method to separate peptides, depending on their distribution between the mobile and 
stationary phase. Subsequently to HPLC, characterization of the purified peptide can be 
performed by Mass spectrometry. 
1.4.8.1 High performance liquid chromatography 
 The frequently used HPLC methods are size- exclusion HPLC, ion exchange HPLC and 
reversed-phase HPLC (RP-HPLC). The most preferred choice of HLPC used for peptide 
separation is RP-HPLC due to its efficiency, speed and excellent resolving ability. Therefore it 
can separate peptides that are nearly identical in sequence. This method is useful for both 
analytical and preparative separations.
11, 42, 43
 
The separation of peptides is mainly carried out at pH values below pH 3. Here acidic 
volatile mobile phases such as aqueous TFA and acetonitrile systems are used. Since TFA is 
volatile it eliminates the desalting step of the peptides. Undesired ionic interaction between 
positively charged amino acid moieties and unfunctionalized silanol groups of the silica based 
stationary phase are avoided by the acidity of the mobile phase.
43 
The chromatographic behavior of peptides can be influenced by counter ions. Peptides 
are charged at most pH values due to their zwitterionic nature. Therefore the anionic counterion 
TFA
-
 can neutralize positively charged basic side chains. And cationic counterions such as 
triethylammonium can be used to neutralize negatively charged acidic side chains. The TFA 
concentration range that can be used is 0.2- 0.25% to separate peptides. In order to separate 
hydrophobic peptides a mobile phase with a high ionic strength is used. To achieve this sodium 
chloride or ammonium sulfate is used in high concentrations of 1-2 mol/l. Here the salts attract 
water allowing hydrophobic interactions of the peptides and stationary phase to occur.
11, 43
 
Next the peptide is eluted by the use of aqueous and nonpolar mobile phase. Nonpolar 
solvents such as acetonitrile, methanol, ethanol, tetrahydrofuran, 2-propanol can be used. Here 
the gradient of the nonpolar solvent is gradually increased until the peptide is eluted. The 
preferred RP-HPLC packing material for the stationary phase is funcionalized silica based 






The mechanism by which peptides are separated by RP-HPLC involves adsorption and 
desorption of the peptide between the mobile and stationary phases. Peptides are too bulky to 
partition into the hydrophobic stationary phase therefore they adsorb onto the hydrophobic 
surface and remain adsorbed until the organic solvent in the mobile phase reaches a 
concentration that could desorbs the peptide into the mobile phase and are eluted (Figure 1.13).
44
 
Next the eluted peptides are detected by means of ultraviolet (UV) light detection. 
Peptide bonds absorb UV at the far UV region generally at 210-220 nm. However if the peptide 
contains tyrosin, phenylalanine or tryptophan amino acid residues they can also absorb in the UV 




Figure 1.13:- Separation of peptides in RP column by absorption and desorption method.
44 
1.4.8.2 Peptide Characterization by Mass Specrometry 
 After purifying the peptide sequence by HPLC, it should be characterized to identify the 
correct peptide sequence. Since there could be peptides that were synthesized half way through 
or close to the final peptide sequence. The best technique used to analyze peptides is mass 
spectrometry (MS). The advantages of using MS are that peptides can be analyzed at a low 
detection limit of 1 pmol. It also provides fast and accurate results of the peptides molecular 
weight giving rise to instant identification. Nowadays there are instruments containing both 







Separation of molecules in MS is based on the size and charge of the molecule. For the 
analysis to be done the molecules that are in solution or solid phase should be converted into gas 
phase ions. To achieve this, the capillary that carries the analyte solution is subjected to a voltage 
difference which creates small charged droplets with many analyte particles in it. The droplets 
are evaporated until the surface tension of the droplet cannot hold these analytes in due to the 
charge that builds up on its surface. Therefore the droplets burst releasing bare ions of the 
analyte (Figure 1.15).
11 









 Next the ions are separated depending on their mass-to-charge ratio in vacuum using the 
mass analyzer. These ions are detected by the charge induced or current produced when it hits 
the detector, which is mainly an electron multiplier. This next produces a mass spectrum of the 
analyte.
11 
1.4.8.3 Prediction of Peptide Properties 
 Nowadays peptide properties can be predicted through online software tools. They can 
calculate the peptides molecular weight, acidic, basic and neutral residue compositions, its 
hydrophobic nature, isoelectric point, charge and their structure prediction just by entering the 
peptide sequence in the software. This is a convenient method to get instant information about 
any peptide.  
 The properties of the peptide that we have used in our research has been predicted by the 
peptide property calculator of the Biosyn website; 
(http://www.biosyn.com/PeptidePropertyCalculator / PeptidePropertyCalculator.aspx) which is 
supported by a biotechnology company called Bio-synthesis, Inc. The properties predicted are as 
below; 
CGKRK(D[KLAKLAKKLAKLAK])PLFAERL include a molecular weight of 2923.87 g/mol 
and its sequence composition consists of 3.85% acidic residues, 7.69% neutral residues, 38.46 % 
basic residues and is 50% hydrophobic in nature. It has an isoelectric point of 11.47 and a charge 
of +9. Its (D[KLAKLAKKLAKLAK]) sequence is an alpha helical structure, its CG part can 
form turns in the peptide and its PL part can be responsible for forming beta structures (Figure 
1.16). 





1.5 Iron Chelators  
 Metal-ion chemistry of transition metal chelators has a wide range of important 
implications in chemical and biochemical areas.
46
 These chelators are polydentate ligands, which 
from stable complexes with hard Lewis bases as donor atoms such as O, F, or with soft Lewis 
bases as N and S.
47, 48 
 Metal chelators are known to be involved in various metabolic and cellular pathways. 
Examples can be found in the photosynthesis in plants using chlorophylls (Figure 1.17), 





Figure 1.17:- A. Porphyrin of hemoglobin (http://en.wikipedia.org/wiki/File:Heme.svg)
49
 




 Among the diverse group of metal chelators, iron chelators show a wide variety of 
applications. They have been used against iron overload diseases, as antimicrobial agents, 
antimalarial agents, anti-inflammatory and anticancer agents. In the past few years great interest 
has been shown in iron chelators due to their anticancer activity.
51 
 
Metal selectivity and metal-ligand complex stability are the properties that govern the 




complexes the specifications such as metal selectivity, affinity, kinetic stability of the complex 
and bioavailability and toxicity should be carefully considered in designing iron (III) chelators.
51 
 For the proliferation of cancer cells, iron is needed as an essential micro nutrient for its 
cell cycle progression and DNA synthesis.
52, 53
 Therefore depriving cancer cells of iron using 
iron chelators can be used as a therapeutic approach for against cancer.
54
 
1.5.1 Bioinorganic Chemistry of Iron 
In the earth’s crust iron (Fe) comes fourth after O, Si and Al when the number of atoms are 
counted. Counting by weight, it is the 2
nd




Iron plays an important role in the metabolism of plants and animals. It is an essential 
micronutrient for both. However, it is toxic in larger quantities. Iron is the most important 
transition metal element in biological processes such as;
47 
 As oxygen carrier in blood through hemoglobin. 
 For oxygen storage in muscular tissues by myoglobin. 
 As an electron carrier in cytochromes and electron transfer in ferredoxins in 
            plants. 
 For iron (Fe) storage and transport using ferritin and transferrin (Tf) proteins. 
 In various enzymes, such as ribonucleotide reductase, catalase and peroxidase. 
 
 The total iron level maintained in a normal human body is 4 g, which is absorbed through 
food as ferrous ion (Fe
2+
). Since iron is required in small amounts it is recycled in the body. The 
iron absorbed is bound to transferrin, which transports Fe to the bone marrow converting it into 
ferritin. The majority of iron is bound to hemoglobin. About 20-30 % is bound to the iron storing 
protein ferritin and its lysosomal degradation product hemosiderin. 10 % of iron is present in 
myoglobin, cytochromes and other iron containing enzymes.
47, 55, 56
 
 Only 1-3 mg/day of iron is absorbed by humans and about the same amount of iron is lost 
by cell desquamatation. Cellular iron is tightly controlled by the transferrin receptor (TfR) and 









Figure 1.18:- Iron absorption, transportation and storage in the body. 




1.5.2 Iron in Cancer 
 The metabolism of iron in cancer cells is altered. Cancer cells have an increased need for 
iron to facilitate their high proliferating rate.
32,58
 The iron uptake into cancer cells is increased by 
the elevation of iron regulatory proteins such as transferrin receptors (Figure 1.19).
55
 
 The need of iron is essential for various cellular processors such as cell proliferation, 
DNA synthesis and mitochondrial electron transport. Iron is important for the function of 
ribonucleotide reductase, which is an enzyme that reduces ribonucleotides to 
deoxyribonucleotides for DNA synthesis and repair. This is the rate-controlling step of DNA 
biosynthesis. This enzyme is closely correlated with cellular replication in the G1-S phase of the 
cell cycle. Since deoxyribonucleoside triphosphates are in low concentrations in cells, it would 
be a good strategy to inhibit the enzyme, ribonucleotide reductase. This, in turn, causes inhibition 






 Manipulating the iron content in the cancer cells could be a good strategy to destroy 
cancer cells. This can be done by the use of iron chelators. Iron chelators will have a double 
impact: Firstly, they will be depleting iron through chelation and inhibiting ribonucleotide 
reductase, thus inhibiting cell proliferation. The second method is that iron chelators can be used 
to bind to intrasomal iron to form redox active chelators to produce cytotoxic reactice oxygen 






Figure 1.19:- Iron regulation in normal and cancer cells.  
The iron regulatory proteins or chemistry involved in cellular metabolism include FeIII-Tf, iron 
III bound to transferrin; FPN, ferroportin; HAMP, hepcidin; LIP, labile iron pool; and TfR1, 
transferring receptor. In cancer cells, compared to normal cells LIP is higher; HAMP is higher; 
FPN is lower; and there are more of TfR1 as well as potential extracellular sources of iron such 
as macrophages and lipocalins.
55
 
1.5.3 Role of Lysosomes and Mitochondria in programmed cell death         
 In order to find a suitable method to stop the uncontrolled and rapid cellular proliferation 
of cancer cells, it would be a better strategy to trigger programmed cell death in these cells than 




 To understand how to trigger apoptosis in cancer cells the answer may be found by 
studying normal cellular mechanisms that mediate cell death.
58
 
 The two main organelles that are involved in apoptosis are the mitochondria and 
lysosome. It is well known that reactive oxygen species that are produced due to oxidative stress 




 Resent research shows that the lysosome also plays a major role in apoptosis. Lysosomes 
are vacuolar organelles, which are acidic and contain hydrolytic enzymes. Their function is to 
degrade intra- and extra-cellular substrates that have been taken up through autophagy and 
endocytosis, and to recycle biomolecules, such as sugar, amino acids and fatty acids.
32, 60
 
 Autophagy of organelles, such as mitochondria and macromolecules                             
(e.g. metalloproteins, cytochromes, hemoglobin, myoglobin, catalase and other enzymes) lead to 












 The acidic environment (pH 4.5-5.5) and the presence of reducing agents such as cysteine 
and glutathione reduce the ferric ion (Fe(III)) to the redox active ferrous ion (Fe(II)) form. 
Superoxide anion radicals, which are formed in lysosomes due to mitochondrial degradation, can 




 The redox active ferrous ion (Fe
2+
) reacts with hydrogen peroxide (H2O2) through the 
Fenton reaction producing highly toxic hydroxyl radicals (HO
•
). Here oxidized ferric ion (Fe
3+
) 
is reduced back to Ferrous ion via the Haber Weiss reaction with superoxide anion. These toxic 





Figure 1.21:- The Fenton reaction.
55 
 
 As a result of higher level of oxidative stress the lysosomal membranes get damaged due 
to high levels of oxidants or iron overload. As a consequence, lysosomal enzymes are released 
into the cytosol, triggering apoptosis.
32
 ROS can also disrupt electron transfer in mitochondria 
and cause apoptosis.
61
 These two pathways can be activated independent from each other, 
however, synergy can be observed. 
 Therefore, by manipulating iron concentrations in the lysosomes of cancer cells, we can 
trigger apoptosis. Iron chelators form complexes with iron, transforming them into Fe(II)-species 
with significantly higher redox activity than uncomplexed Fe(II). These redox active Fe(II) 
complexes can facilitate ROS formation and induce apoptosis in cancer cells (Figure 1.22).
55  
1.5.4 Iron Chelators for Therapy 
 In chelation therapy the iron concentration in the body should be maintained at normal 








 The iron, which is stored as ferritin or hemosiderin is not readily accessible by chelators 
at a convinient rate, because it is bound too tightly. Therefore, chelation therapy depends on the 
weakly bound low-molecular- weight iron, referred to as ‘labile iron pool’ (LIP). It comprises of 




) and represents < 5 % of the total iron in the cell (50-100 µM). 
This accessible iron is bound to various ligands with low affinity.
51 
 
 Figure 1.22:- A. Effects of cancer and normal cells treated with iron chelators. 







 The LIP iron is complexed with low-molecular weight organic chelators such as organic 
anions (phosphates, carbohydrates and carboxylates), polypeptides, citrate, phospholipids, 
nucleotides and nucleosides. These LIP’s are available for interaction with iron chelators, 
because the latter bind (usually Fe(II)) more tightly.
51, 62, 63
 
 Iron chelation therapy was traditionally used to relieve iron overload in patients with 
diseases such as β thalassemia, sickle cell disease and myelodysplasia, where the patients 
received multiple blood transfusions as treatment.
64, 65
 
 However, there is an emerging need for iron chelators for diseases such as cardiovascular 
diseases, atherosclerosis, neurodegenerative diseases, chronic inflammatory diseases and cancer 
where oxidative stress plays a major cause.
65
 
 Naturally synthesized chelators are found in bacteria and fungi called siderophores. They 
are secreted to scavenge and absorb iron from the environment. Desferrioxamine is an example 
for one of these natural chelators.
58
 




 depend on their chemical properties and 
binding with iron in iron:chelator ratios of 1:1, 1:2, 1:3. They also have the ability to favor or 
restrict of binding iron to redox cycle.
58 
 
1.5.5   Designing Iron Chelators 
  Iron chelators should be designed by considering the following characteristics; metal 
selectivity and affinity, kinetic stability of the complex, bioavailability and toxicity. These 
characteristics are important for clinical use.
51, 64
 
1.5.5.1 Metal Selectivity and Affinity 
 Metal selectivity and ligand-metal complex stability are the major properties that are 
important in designing iron chelators.
66
 
 Due to the incompletely filled d- orbital’s of iron it has has several valences. Its most 






 Iron chelators are usually small 
molecules with molecular mass of approximately 100-900 Da.
58





 oxidation states by following the ‘hard’ and ‘soft’ acid and base concept.
64, 66
 
 Chelators containing ‘soft’ donor atoms such as nitrogen and sulfur such compounds 




Lewis acid iron (II). Fe (II) has a high electron density and lower charge density. Which poorly 
interacts with oxygen donor atom containing compounds. It is also unfavorable to maintain its 
optimal complex geometry due to low ratio of charge to ionic radius of Fe (II) compared with Fe 
(III).
48, 64
 They can also bind to other biological metals such as copper (II) and zinc (II) ions 
(Table 1.4). Therefore it is close to impossible to synthesize non-toxic iron (II) selective 
chelators.
66, 67 




Figure 1.23:- Structures of iron chelators. 
 
Ligand 
Log Cumulative stability Constant 
Fe (III) Al(III) Ga(III) Cu(III) Zn(II) Fe(II) 
Desferrioxamine (DFO) 30.6 25.0 27.6 14.1 11.1 7.2 
2,2ʹ-bipyridyl 16.3 - 7.7 16.9 13.2 17.2 




40.2 - - 24.9 13.5 17.5 
Acetohydroxamic acid 28.3 21.5 - 7.9 9.6 8.5 
Deferiprone 37.2 35.8 32.6 21.7 13.5 12.1 
EDTA 25.1 16.5 21.0 18.8 16.5 14.3 


















































 Oxygen containing chelators are more selective to high-spin d
5
 configuration of iron (III). 
It has a radius of 0.65
o
A and is a spherically symmetrical tri-fold positive cation with a high 
charge density. Ligand field stabilization energy is not provided for this configuration, however 
it is kinetically stable. It also forms strong ionic interactions with weakly polarizable oxygen 
atoms in ligand such as oxyanions, hydroxamates and catecholates, which prefer tribasic metal 
cations than dibasic cations.
48, 51, 66
 
 Furthermore, when the charge on the oxygen atom increases the affinity towards iron (III) 
also increases. The pKa values of oxygen also affects the affinity towards iron (III). Therefore 
increasing the affinity, when the pKa value increases (Table 1.5).
47, 68
 
 Most tribasic ions such as aluminium (III) and gallium (III) are not essential for cells than 
iron (III). Therefore iron (III) chelators are more suitable for clinical use. High affinity iron (III) 
chelators can also chelate iron (II) and undergo oxidation in aerobic conditions to form iron (III). 




 The common geometry of iron (III) chelators is octahedral where six ligands are arranged 
around the iron with minimum ligand repulsion. And it favors the thermodynamically stable 
high- spin iron (III) species. However this octahedral field may be distorted or the incorporation 













Compound Ionic Structure 
 


















α-Aminocarboxylate (2.5, 9.5) 
 
 








1.5.5.2 Thermodynamic Stability of Iron Complexes 
 In biological environments the iron chelators must compete with biological iron binding 
ligands. The important factors to consider, when considering them as therepeutic agent, are the 
affinity of these chelators towards iron and stoichiometry of iron binding.
58 
 The classification of ligands is done according to the number of donor atoms available in 
a ligand. Therefore if a ligand contains 2 donor atoms they are referred to as bidentate ligands 
and if they contain 3 donor atoms tridentate, likewise 4 atoms tetradentate, 6 atoms hexadentate 
or in general multidentate ligands. 
 The number and size of chelate rings formed in the ligand-metal complex is important 
when determining the thermodynamic stability of the metal complex. Therefore increasing 
stability can be done by incorporation of all donor atoms into a single ligand creating a 
hexadentate ligand. By increasing the number of donor atoms in the chelator we can increase the 
number of chelating rings. Ring sizes of five and six donor atoms are the most favorable. For an 
example a metal with co-ordination number six forms 3 rings with a bidentate ligand and five 














The equilibrium between a metal ion (M) and ligand (L) can be expressed in the equation 1.  
 








 When the ligand is completely deprotonated the strength of metal-ligand complex include 
the parameters overall formation constant (β) which is equal to equilibrium constant K    
(equation 2). But it is important to consider that the chelators are not fully deprotonated under 
physiological conditions and it is useful to use the conditional stability constant KpH.
58
 
 The value pM is most important since it takes into account the stoichiometry of metal 
complexes formed by different metal complexes. pM is given by the equation 3, at a given pH 





 The ligand metal complex stability increase is due to the entropic changes produced when 





 A comparison of pM values of bidentate, tridentate and hexadentate chelators are shown 
in table 1.6.  Here we can see that the ligand concentration can also influence the affinity of 
metal: ligand complex.
42
 For an example 3 log units of stability is observed in the hexadentate 
ligand MECAM (Figure 1.23) than the bidentate lidgand N,N-dimethyl-2,3-dihydroxybenzamide 
(DMB) (Figure 1.23) with iron (III). Although this is so there are other hexadentate ligands that 
bind (III) even more tightly, such as enterobactin (Figure 1.23).
66
 
 Here the stability of the complex increases when the conformational space of the free 
ligand is small. The entropy difference decreases when the flexibility of this ligand and its iron 
complex decreases, this is called “pre-organization”.
58,66
 The pocket size for iron can be designed 







 since its donor atom arranges around a space that accommodates Fe
2+
 





 EDTA (Figure 1.23) can change its conformation since it has several pendant arms but 
some ligands such as the planar tridentate ligands PIH and ICL670A which are rigid structures 
can not change their conformations for ligand exchange, providing their kinetic inertness and 






























 Log Stability constant 
(logK7.4) 
1:1 Stoichiometry 
DFO 26.6 25.6 
O-Trensox 29.5 28.5 
ICRF-198 18.8 17.8 
DTPA 24.7 23.8 
EDTA 23.2 22.2 
1:2 Stoichiometry 
PIH 23.2 27.4 
Desferithiocine 20.3 24.5 
ICL670A 25.4 29.6 
1:3 Stoichiometry 
Deferiprone 20.0 29.4 
Hydroxyquinoline 22.9 32.4 
1,10-Phenanthroline 6.0 14.4 
MECAM 28.0 43.0 









 M and [ligand]total = 10
-5








 can also affect the redox reaction. The 
redox potential (E
0
) at pH 7.0 of aquated iron is 110mV (equation 4), which is within the 
biological range (-320-460mV) accessible to intracellular oxidants and reductants, such as 
NADPH and thiols. This means that both redox forms are present in biological environment. 
Therefore due to the chelators affinity of one oxidation state over the other, can lead to changes 
in th redox equilibrium.
58,70 
 
 Redox potential that are above or below the range accessible by biological systems show 




1.5.5.3 Lipophilicity and Molecular Weight for Clinical Application 
 For a chelator to perform its biological effect, it should be able to reach its target site in 
high concentration. Since biological membranes are phospholipid bilayers and are hydrophobic 
in nature, the iron chelators should be lipophilic. Uncharged compounds are preferred. 
Appreciable lipid solubility can be obtained by the octanol: water partition coefficient (Log P) 
ranging from > - 0.7 to < 5 log P values. However, they should not be highly hydrophobic, since 
they otherwise will be able to penetrate highly regulated barriers, such the blood brain barrier, 
and placental barriers, thus producing toxic side effects.
66,71
 
 An iron chelator should have a molecular weight of  < 500 Da in order to have >70% 
penetration into the cells. Most hexadentate ligands have a higher molecular weight, making 
them less available. An example is DFO having a molecular weight > 500 Da. Smaller molecular 
weight chelators such as EDTA (292 Da) may be too small, thus causing toxicity. Bidentate and 
tridentate ligands have lower molecular weight compared to DFO, showing higher absorption.
66
 
 Another factor that influences the lipophilicity and effectiveness of chelators is the pH. 
The pFe
3+
 vs. pH plots can be used to compare the effective binding of the chelators with iron 
(III) at different pH values. Iron (III) forms stable bonds with weakly polarizable atoms, such as 
oxygen. The affinity of iron binding with chelators containing oxygen atoms depends on the pKa 





value. For example, the high charge density on the oxygen atoms of catechol (Figure 1.23) shows 
high affinity for protons. Therefore, the binding of catechols to cations is pH sensitive. At pH 7 
the complex bears a net charge and cannot permeate membranes. However, catechol can 




Figure 1.25:- Speciation plot of iron(III) in the presence of; 
(A)  N,N-dimethyl-2,3-dihydroxybenzamide  




 M and [ligand]total = 10
-5
 M    








         
 
 In these complexes the iron atom is able to interact with H2O2 to form hydroxyl radicals, 
since it is not completely protected from the solvent. 
 Hydroxamates have lower affinity towards iron than catechol. They form neutral tris-
complexes with iron (III) which can permeate through membranes easily. Since hydroxamates 
low affinity towards protons there is less H
+
 interference at physiological pH (Figure 1.25B).
66 
1.5.5.4 Toxicity 
 Toxicity by chelators is due to factors such as lack of selectivity of metal ions which lead 




. Toxicity can also occur by inhibition 
of important iron containing metalloenzymes such as ribonucleotide reductase, which is 





1.5.6 Redox Active Iron Complexes Generating Toxic Free Radicals 
 Chelators with carboxylate and nitrogen have affinity towards both bivalent and trivalent 
ions. Chelators containing oxygen have a strong affinity towards tribasic cations. For redox 
activity to occur chelators containing nitrogen have a higher redox potential. These complexes 
redox cycle under aerobic conditions producing oxygen radicals.
66
 
1.5.7 A Suitable Iron Chelator for Cancer Treatment 
 The factors that would be preferred as an anti-cancer agent in an iron chelator; 
− Have considerable lipophilicity 
− Capable of generating reactive oxygen species 
− Inhibit ribonucleotide reductase activity 
 The ligands that perfectly fit to these requirements are the thiosemicarbazone compounds 
(Figure 1.26). They are a set of tridentate ligands which contain nitrogen and sulfur and form 
2:1, ligand: iron complexes. They contain aromatic rings with nitrogen such as pyridine or 








 and also trivalent ions. Binding 
occurs through sulfur and heterocyclic and imine nitrogen donors, which are soft atoms, 
producing high affinity towards these transition metals.
58 
 Among this family of compounds the chelator Dp44mT shows promising anti- cancer 
activity at nanomolar concentrations. 
1.5.8  Experimental Evidence of Anti Cancer activity of Thiosemicarbazones 
1.5.8.1 pH Effect 
 The neutral from of the thiosemicarbazones is preferred since it is important in 
permeating through the cell membranes.
52
  
 As in figure 1.27 of the speciation plot for HDp4eT the protonated form is dominant 
below pH 4 (diamond line) and the deprotonated form is dominant above pH 11 (broken line).  
 The charge neutral (solid line) form is dominant at physiological pH. This demonstrates 
that these ligands are in their neutral form in biological systems and can permeate through cell 









Figure 1.26:- Structural formuas of Pyridoxal isonicotinoyl hydrazone (H2PIH),  
2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (H2NIH or 311), 2-hydroxy-1-
naphthylaldehyde thiosemicarbazone (H2NT), di-2-pyridyl ketone isonicotinoyl hydrazone 
(HPKIH), di-2-pyridyl ketone thiosemicarbazone (HDpT), di-2-pyridyl ketone 4-methyl-3-
thiosemicarbazone (HDp4mT), di-2-pyridyl ketone 4-ethyl-3-thiosemicarbazone (HDp4eT), di-
2-pyridyl ketone 4,4-dimethyl-3-thiosemicarbazone (HDp44mT), di-2-pyridyl ketone 4-phenyl-
3-thiosemicarbazone (HDp4pT), di-2-pyridyl ketone-4-allyl-3-thiosemicarbazone (HDp4aT). 






Figure 1.27:- Speciation plot for [H2Dp4eT]+ (diamonds), HDp4eT (solid curve), and [Dp4eT]- 
(broken curve) as a function of pH.
70
  
1.5.8.2 Lipophilicity of the Ligands 
 The lipophilicity of a chelator is another property of its ability to permeate membranes. 
This is determined by its partition coefficient of octanol:water (log P) values (Table 1.7).  
 













 The compounds with log P values greater than 1.5 are moderately lipophilic. HDpT is 
mostly hydrophilic since it bears 2 protons on the S=C-NH2. The rest of the other chelators are 
lipophilic due to presence of 1 or 2 hydrophobic substituents (Figure 1.25). According to the data 















1.5.8.3 Effects of Antiproliferating Activity 
 The antiproliferating activity occurs due to inhibition of ribonucleotide reductase 
enzyme.
45
 Ribonucleotide reductase is required for the synthesis of large amounts of DNA that is 
required in fast-dividing cells, as this is the case in cancer. 
 





























0.18 ± 0.02 
1.53 ± 0.21 








0.05 ± 0.03 
1.21 ± 0.47 








0.01 ± 0.01 
0.42 ± 0.08 








0.02 ± 0.01 
0.69 ± 0.24 








0.01 ± 0.01 
0.21 ± 0.05 





 Antiproliferating activity of the iron chelators can be determined by the MTT assay. 
From the IC50 data shown in table 5, the control DFO showed low antiproliferating activity. 
However, among the HDpT analogues HDpT showed least activity. And Dp4eT, Dp44mT and 
Dp4pT shows marked efficacy at inhibiting cell proliferation.
70 
 Dp44mT was also found to be effective against 28 cancer cells lines with an average IC50 











Figure 1.28:- Dp44mT markedly inhibits clonogenic formation 
37 
                                 
(DFO: desferrioxamine, DOX: doxorubicine) 
1.5.8.4 Redox Activity 
 The redox potentials of HDpT chelators are shown to be 300-400 mV lower than other 


























 From all of these results we can could say that a thiosemicarbazone analogue close in 
structure to either Dp4eT, Dp44mT or Dp4pT to be a preferentially good candidate as an iron 
chelator used as an anti caner agent.  
 
1.6 Iron/ Iron Oxide Nanoparticles 
 The development of nanotechnology has dramatically increased in the last couple of 
decades. Scientific studies have lead to the understanding of the behavior of the nanoparticles 
such as stability, control of surfactants, particle size, suitable materials to produce nanoparticles 
and physical behavior. These studies provide a good insight that will lead to nanoparticles that 
can be tailored accordingly for biomedical applications and diagnostics.
72, 73
 
 Iron/iron oxide (Fe/Fe3O4) nanoparticles have been used for about 40 years for various 
medical applications. The physical and chemical properties of these nanoparticles do not contain 
the characteristics of either the atom or the bulk counterparts and exhibit superparamagnetic 
properties. These superparamagnetic nanoparticles can be used for several biomedical 
applications due to their specific mesoscopic physical, chemical, thermal and mechanical 
properties and with proper surface chemistry. The biomedical applications include;
72, 73 
 Magnetic resonance imaging (MRI) 
 Drug delivery 
 Hyperthermia 
 Tissue repair 
 Immunoassays 
 Detoxification of biological fluids 
 Cell separation 
 Magnetofection 
 
 In order to achieve these in vivo applications they need to have a small particle size 
smaller that 100 nm, a narrow particle size distribution, they should have a surface coating which 






1.6.1 Magnetic Iron/ Iron Oxide Nanoparticles for Biomedical Applications 
There are several types of magnetic Fe/Fe3O4 nanoparticles that have been studied and 
among them are maghemite (γ-Fe2O3) and magnetite (Fe3O4) that are 5-20 nm in size. Magnetite 
is mostly used since it is more biocompatible than maghemite. Magnetite forms a fcc closed 
packing cubic inverse spinel structure. Here the iron cations are occupied at the interstitial 
tetrahedral and octahedral sites. It is a half- metallic material and has quantum size effects and a 
large surface area changing its magnetic properties into superparamagnetic properties since a 
particle is considered as a single magnetic domain.
72, 74
 
The synthesis of nanoparticles is challenging in producing nanoparticles with specific 
size and shape. There are many methods to synthesize nanoparticles such as Ostwald ripening, 
water-in-oil microemulsion method. In the synthesis of nanoparticles there are two stages 
involved where first when the concentration of the species reaches its critical supersaturation a 
short burst of nucleation occurs, next, a slow growth of nuclei occurs by the diffusion of solutes 




The size and shape of the nanoparticles can be controlled by adjusting the pH, ionic 





 ratio used in the reaction. The use of surface modifiers is crucial to stabilize the 
Fe/Fe3O4 nanoparticles from aggregation in both biological medium and magnetic field. This can 




Stabilizers that can be used are;
72, 73 
 Carboxylates, phosphates which are known to bind to the surface of magnetites. 
 Inorganic material such as silica or gold can be used to coat the nanoparticles. They can 
also help in binding other biological ligands. 
 Polymer stabilizers such as dextran, polyethylene glycol, polyvinyl alcohol and chitosan. 
 Long chain surfactants such as oleic acid, stearic acid. 
To prevent the Fe/Fe3O4 nanoparticles from oxidation and agglomeration an inert gas 
such as argon or nitrogen can be bubbled through the reaction solution during the synthesis. It 












1.6.1.1 Drug Delivery 
Magnetic nanoparticles show promising applications in drug delivery. The surface of the 
nanoparticles can be modified with drugs and various biological ligands (e.g. tumor targeting 
peptides, proapoptotic peptides, DNA, RNA and antibodies), which target tumors or specific 
organs. These surface modified nanoparticles are able to reduce drug doses and side effects to 
normal cells, as well as the costs associated with drug treatment. This is most important in cancer 
treatment since therapeutic nanoplatforms would specifically target the cancer cells and release 






Fe/Fe3O4 nanoparticles that are not surface modified have a short blood half-life of 
several minutes and are mainly used for imaging of liver, spleen and gastrointestinal tract. 
However surface modified Fe/Fe3O4 nanoparticles have long blood circulating times of hours (48 
hrs) and are useful for imaging vascular compartment (magnetic resonance angiography), lymph 
nodes, perfusion imaging, receptor imaging and target specific imaging.
72 
These magnetic nanoparticles can be magnetically controlled in the vascular by an 
external magnetic field. Therefore, they can be magnetically guided and can be retained into a 
specific location. For instance, magnetic nanoparticles can be retained at the tumor site, where it 
can release its payload and carry out its activity.
72
 
The internalization of nanoparticles into cells depends on their size. Nanoparticles 
administered which range from 10 nm to 100 nm are the ideal size for intravenous injection. 
They show long circulation times and are small enough to avoid rapid clearance by the 
reticuloendothelial system. They can also penetrate through capillaries prior to systemic 
clearance and are the most effective particle size for biological application. Particles larger than 
200 nm in diameter are removed by the spleen by mechanical filtration and are ultimately 
removed by phagocyte system reducing its blood circulation time. Particles with diameters less 
than 10 nm are rapidly removed by extravasation and renal clearance. These effects greatly 
reduce their blood circulation time.
72, 73 
Since cancer cells proliferate at a higher ratio than normal cells they need to meet the 
high demand of nutrients. Therefore, new blood vessels have to be formed when the cancer 
grows. This process is called angiogenesis. These blood vessels are leaky with average pore size 
of 100-600 nm. The leaky pores can facilitate nanoparticles to diffuse into the cancer tissues 
thereby making it a good carrier for drugs into cancer cells.
3
 
1.6.1.2 Magnetic Resonance Imaging (MRI) 
The use of superparamagnetic Fe/Fe3O4 nanoparticles (SPIO) as contrasting agents play 
an important role for MRI. SPIO tagged with certain specific homing peptides or antibodies 
allows early detection of pathological tissues, such as the differentiation of cancerous tissues 
form normal healthy tissues (Figure 1.30). MRI can also be used to track cells in the body that 
have been tagged with SPIO and can also be used to detect apoptosis where the MR image 









Figure 1.30:- MRI Using Fe/Fe3O4-NPs, Delivered by NPC cells, B16F10 Lung Tumors in 
Black Mice. 
                     A: Control  
                     B: Accumulation of the Fe/Fe3O4/stealth nanoparticles in lung melanomas 
All results were obtained in an 400MHz at the Oklahoma Medical Research Foundation Nuclear 
Magnetic Resonance Core. These figures were adopted form Dr. Thilani Samarakoon’s thesis, 
Kansas State University, 2010 
 
The contrasting ability of SPIO is due to their high transverse relaxivity. In a magnetic 
fluid, ferromagnetic particles dispersed in a liquid, which forms a colloid. Each crystal in the 
colloid suspension is small in size and is fully magnetized forming nanomagnets and is 
composed of single domains. When a SPIO is subjected to an external magnetic field, the entire 
crystal aligns with the applied field due to the single crystal nature, which enhances the magnetic 
flux. Changes in MRI signal are produced through disturbances caused in the local magnetic 
field induced by large magnetic moments causing rapid dephasing of surrounding protons.
72, 73, 75
 
The MRI contrast relies on the relaxation of these crystals back to equilibrium. There are 
two relaxation processors involved, which are commonly described as Néel relaxation and 
Brownian relaxation (Figure 1.31).  
The Néel relaxation occurs in sufficiently small nanoparticles and is defined as the time 
taken for the particles to return back to equilibrium after perturbation. Brownian relaxation is 
detected in larger particles and characterizes the viscous rotation of the entire particle. Therefore, 










Figure 1.31:- Illustration of Néel relaxation and Brownian relaxation.
73 
1.6.1.3 Hyperthermia 
The use of heat (hyperthermia) as a treatment method for tumors has been practiced for 
centuries. It is known that tumor cells are more sensitive to heat than normal healthy cells. When 
the temperature is increased more than 43
0
C tumor cells are destroyed. However normal cells 
survive at higher temperatures. Therefore by exposing tumor cells to increased temperatures the 
tumor tissue can be destroyed by hyperthermia.
 
Heating methods that were used to destroy 
tumors included the use of a hot water bath, pyrogens (bacterial toxins), perfusion heating, high 
frequency radiation and magnetic fluid hyperthermia.
72, 73
 
Ferrofluids of superparamagnetic Fe/Fe3O4 nanoparticles when subjected to an 
alternating magnetic field they start to spin (Figure 1.32), generating heat. Therefore, by 
embedding magnetic particles into the tumor site and exposing it to an alternating magnetic field 
(AMF) heat will be generated depending on magnetic properties of the material, the strength of 









Figure 1.32:- Heat generation by superparamagnetic and/or ferromagnetic Fe/Fe3O4 
nanoparticles when subjected to an alternating magnetic field. 
 
 The magnetic energy of the nanoparticles shows a synoidal wave when subjected to an 












The specific absorption rate (SAR) is the parameter that determines heating of the tissues. 
It is defined as; “The rate of which electromagnetic energy is absorbed by a unit mass of 
biological material”. Its units are in calories per kilogram. SAR is proportional to the increase in 
temperature (ΔT/ Δt) and is calculated by the equation below (Equation 6). 
 
                                                                                                                                                                                                                                             
 
Where; 
           P   =   Electromagnetic wave power absorbed by the sample 
          me   =   Mass of the sample 
          Ce  =   Specific heat capacity of the sample 
 
The use of low-frequency magnetic wave ranging around 100 kHz to 400 kHz is 
appropriate to be exposed to tissues containing ferrofluids. This specific range is used to control 









1.7.1 Synthesis of the Thiosemicarbazone Analogue 
 Potassium hydroxide (8.36 g, 0.14 mol) was dissolved in 90% ethanol (30 ml) this 
mixture was cooled in an ice bath. To this mixture cold hydrazine hydrate (7.29 ml, 0.14 mol) 
was added slowly while stirring. Next cold carbon disulfide (9 ml, 0.14 mol) was added drop 
wise with vigorous stirring. The temperature of the reaction mixture was not allowed to rise 
above 6 
0
C during the period of carbon disulfide addition. This reaction mixture was reacted for 
2 hrs. To the same reaction mixture cold methyl iodide (9.27 ml, 0.14 mol) was added slowly 
and further reacted for 30 min. The resultant white product (hydrazinecarbodithioc acid methyl 
ester) was filtered and washed with cold water and dried (70 % yield). This product was next 
recrystallized in hot ethanol and the NMR was taken (Appendix B Figure B.1). This intermediate 
methyl ester product was then refluxed in the presence of di-2-pyridyl ketone at an equivalence 
of 3:1 respectively. Di-2-pyridyl ketone (3.01g, 0.016 mol) was dissolved in 15 ml of ethanol to 
this a catalytic amount of HCl (2.8 ml) was added. Next the methyl ester dissolved in 15 ml of 
ethanol was added to this mixture and refluxed at 100 
0
C for 3 hrs. After 3 hrs cold distilled 
water was added and a yellow color precipitate formed. This precipitate was filtered and washed 
with cold water and was dried. This resulting product was recrystalized by hot ethanol and the 
resulting yellow colored needle shaped crystals were filtered by suction and washed with cold 




H-NMR of this product was taken (Appendix B Figure B.2). The 
reaction scheme can be found in Appendix A Figure A.1. 
1.7.2 Synthesis of the Peptide 
 The peptide sequence CGKRK(D[KLAKLAKKLAKLAK])PLFAERL was synthesized 
according to the protocol discussed in topic 1.4.6.1.  
 The peptide was synthesized on a leucine preloaded trityl resin (H-Leu-2-ClTrt-resin) and 
through many repeating cycles of N-deprotection using piperidine and subsequent amino acid 
coupling with the coupling solution. Amino acid by amino acid the peptide sequence was 
synthesized from the C-terminus to the N-terminus (Figure 1.12). Dried and stored the peptide on 




1.7.3 HPLC Purification of the Peptide 
 The peptide sequence CGKRK(D[KLAKLAKKLAKLAK])PLFAERL was purified using 
the Waters 1525- Binary HPLC pump instrument and Kinetex 5 µ XB- C18 100 A size 250 * 4.6 
mm reverse phase column. The peptide (2.5 mg) was dissolved in equal amounts of 0.2 % TFA 
(125 µl) and acetonitrile (125 µl) and 40 µl was injected into the machine. The peptide was 
purified using 0.2 % TFA as the aqueous solvent and acetonitrile as the organic solvent (table 
1.10).
43
 The purification was achieved through a gradient of aqueous and organic solvent as 
shown below; The HLPC can be found in Appendix B Figure B.6. 
 
Table 1.10:- Solvent gradient of aqueous and organic solvents. 
Time (min) Flow A(aq) B(org) Flow rate A % Flow rate B % 
0 1 99 1 0.99 0.01 
60.00 1 60 40 0.60 0.40 
60.01 0 60 40 - - 
 
1.7.4 Synthesis of the Dopamine Peptide Ligand 
 First the resin with the peptide (150 mg, 0.075 mmol) was swelled in 5 ml of DCM and 
was swirled for 20 mins. The DCM was filtered and the resin was swirled with 2.5 ml of DMF 
for 1 min and was filtered off. Next the peptide sequence was deprotected by reacting with 4 ml 
of 20% piperidine: DMF solution for 1 min and was filtered, this step was repeated and was 
swirled for 10 mins and filtered. The resin was washed 5 times with 2.5 ml of DMF and was 
filtered. The resin with peptide sequence was next reacted with glutaric anhydride (25.67 mg, 
0.225 mmol) for 3 hrs at an equivalence of 1:3 respectively. This step was repeated two more 
times. This was next reacted with dopamine hydrochloride (14.22 mg, 0.075 mmol) at an 
equivalence of 1:1 and HBTU (82.40 mg, 0.217 mmol) at an equivalence of 1:2.9 in 6 ml of the 
DIEA: DMF coupling solution for 30 mins and was filtered off. This step was repeated. The 
resin was washed 4 times with 2.5 ml of DMF for 30 s each and was filtered off. It was next 
washed 5 times with 2.5 ml of DCM for 30 s each and was filtered off.
77
 Next the dopamine 
peptide ligand was cleaved from the resin using 2 ml of the cocktail of 1.9 ml TFA, 0.05 ml TIPS 




precipitated in 15 ml of cold ether and was centrifuged. The precipitated ligand was washed two 
more times with 15 ml of cold ether and the ligand was centrifuged the supernatant was decanted 
and the ligand was dried and stored under argon in a -20 
0
C freezer for later use. The reaction 
scheme is found in Appendix A Figure A.2. 
1.7.5 Synthesis of Core/Shell Fe/Fe3O4 Magnetic Nanoparticles (MNPs) and 
Characterization  
 Fe/Fe3O4 nanoparticles were synthesized by a modified seeded growth procedure, which 
was originally published by Sun et al.
78
 Iron pentacarbonyl (Fe(CO)5) (10.5 ml)  is initially 
thermally decomposed at 200
o
C in octadecene (ODE) (300 ml). This reaction produces Fe(0) 
atoms, which aggregate to form the initial sub-nanometer clusters. The reaction temperature is 
then lowered to 180
o
C. The Fe(0) clusters are capable of catalyzing the thermal decomposition of 
Fe(CO)5. In the presence of the binary ligand system oleylamine (4.5 ml) and 
hexadecylammonium chloride (HAD·HCl) (4.15 g) this process leads to the controlled growth of 
iron(0) nanoparticles (the reaction scheme can be found in Appendix A Figure A.3). Depending 
on the iron pentacarbonyl concentration, initial reaction time and temperature, as well as the 
duration and temperature of the subsequent ripening procedure, near monodisperse 
(polydispersity < 1.03) nanoparticles possessing diameters between 5nm and 100nm can be 
prepared.
79
 The second step in nanoparticle synthesis consists in the defined oxidation of the 
surface Fe(0) to Fe3O4. Dr. Wang has optimized this procedure in the Bossmann group by 
bubbling O2/N2 mixtures through a dispersion of the initially prepared nanoparticles at room 
temperature. By selecting the duration of air oxidation, various chain thicknesses can be 
achieved. As this is shown in TEM (Appendix B Figure B.8), the typical thickness of the outer 
Fe3O4 layer in the nanoparticles that I have synthesized in my thesis (d = 28+/-2 nm) was 2nm. 
 
 This synthetic procedure was scaled up to 100g batches in 2013 in the Bossmann group. 
Kansas State University Research Foundation (KSURF) in collaboration with Kansas State 
University’s Institute for Commercialization (KSU-IC) is currently pursuing a combined patent 
with Battelle Memorial Institute, Columbus, OH. 
 




1.7.6 Powder X-ray diffraction (XRD) of the Fe/Fe3O4 Magnetic Nanoparticles 
Powder X-ray diffraction (XRD) patterns were obtained on a Bruker D8 X-ray 
diffractometer with Cu Kα radiation.
77 
1.7.7 X-ray photoelectron spectroscopy (XPS) of the Fe/Fe3O4 Magnetic Nanoparticles 
 X-ray photoelectron spectroscopy (XPS) data
80
 was recorded with a Perkin–Elmer PHI 
5400 electron spectrometer using acrochromatic Al Kα radiation (1486.6 eV). Analysis was 
carried out under vacuum less than 5 × 10
−9
 Torr and heated to 120 
o
C to remove any adsorbed 
molecules on the surface. The XPS binding energies were measured with a precision of 0.025 
eV. The analyzer pass energy was set to 17.9 eV, the contact time was 50 ms, and the area 
scanned was 4 mm
2
. 
1.7.8 Ligand exchange of Fe/Fe3O4 Nanoparticles with the Dopamine Peptide 
Sequence and Free Dopamine 
 The oleylamine and octadecyl coated Fe/Fe3O4 nanoparticles (500 mg) were reacted with 
the dopamine peptide ligand (50 mg) at a ratio of 10:1 respectively. They were reacted in 10 ml 
of THF (Tetrahydrofuran) under argon overnight. The reaction mixture was centrifuged and the 
supernatant was removed. Next the nanoparticles were reacted with an excess amount of 
dopamine hydrochloride (150 mg) in 10 ml of THF under argon overnight. The reaction mixture 
was centrifuged and the supernatant was removed. The nanoparticles were washed 5 times with 5 
ml of DCM.
77
 And the naoparticles were stored in DCM for future use. The reaction scheme can 
be found in Appendix A Figure A.4. 
 Another batch of nanoparticles was synthesized with just dopamine as their ligand, 
following, principally, the same procedure. 
1.7.9 Coupling of the Thiosemicarbazone Analogue to the Free Dopamine on the 
Fe/Fe3O4 nanoparticles                                        
 Coupling was done in different ratios of the iron chelator thiosemicarbazone analogue: 
free dopamine, dopamine peptide coated Fe/Fe3O4 nanoparticles at ratios of 1: 10, 1: 5, 1: 1,  
5: 1 and 10:1 respectively (Table 1.11). The reaction was done in DMF with two equivalence 
each of EDC, HOBT and 2.5 equivalence of DIEA.
77
 The reaction solution was reacted for four 




 The same reaction procedure was done for the nanoparticle coated with just dopamine.  
 
Table 1.11:- Coupling ratios. 







An example for the calculation involved to prepare the different ratios are as below; 
Surface are of a Fe/Fe3O4 nanoparticles                          =  4πr
2
 
with a diameter of 20 nm                                                  =  4 * 22/ 7 * 10
2
 nm 
                                                                                          =  1257.14 nm
2
 
Space demand of dopamine linker                             =  1.094 nm
2
 





                                                                                =  1149.12 
Volume of Fe/Fe3O4 nanoparticles in 30 mg               =  d = m/ v 
                                                                                 =  v = m/ d 
             =  (30 * 10
-3
)g / 7.84 gml
-1
 
                                                                                 =  3.826 * 10
-3
 ml 

























                                                                                             =  9.132 * 10
14
 
Number of dopamine in the Fe/Fe3O4 nanoparticles          = (9.132 * 10
14
)  * 1149.12 
                                                                                             =  1.049 * 10
18
 
Moles of dopamine in 30 mg of Fe/Fe3O4 nanoparticles    =  (1/ (6.023 * 10
23
)) * (1.049 * 10
18
) 








Reaction of thiosemicarbazone analogue 1: 10 dopamine and dopamine peptide coated 
nanoparticle: 
Moles of thiosemicarbazone to be added  = ((1.742 * 10
-6
) mols/ 10) * 1 
                                                                   = 1.742 * 10
-7
 mols 
Moles of EDC needed to be added           =  ((1.742 * 10
-7
) mols )/ 1) * 2 
                                                                    =  3.454 * 10
-7
 mols 
Moles of HOBT needed to be added         =  ((1.742 * 10
-7
) mols )/ 1) * 2 
                                                                    =  3.454 * 10
-7
 mols 
Moles of DIEA needed to be added          =  ((1.742 * 10
-7
) mols )/ 1) * 2.5 




1.7.10 UV Measurements of Thiosemicarbazone Analogue Coupling with the 
Dopamine on the Nanoparticle 
 UV measurements were taken at UV range from 200- 500 nm. UV measurements were 
taken at different stages of the reaction; 
1. Thiosemicarbazone analogue alone in DMF. 
2. Thiosemicarbazone analogue, EDC, HOBT and DIEA in DMF. 
3. Supernatant of the reaction mixture after adding the nanoparticles. 
4. Supernatant of the reaction mixture after 4 days of reaction. (the nanoparticles were 
centrifuged to take the supernatant). 
5. Reaction mixture of the control after 4 days. The reaction done without nanoparticles. 
(Thiosemicarbazone analogue, EDC, HOBT, DIEA). 
 The measurements were taken for both batches of nanoparticles at the different reaction 
ratios of 1: 10, 1: 5, 1: 1, 5: 1 and 10:1 as mentioned in section 1.7.7; 
 For nanoparticles coated with both dopamine and dopamine peptide ligands. 
 For nanoparticles coated with just dopamine ligands. 





1.7.11 Dynamic Light Scattering (DLS) and Zetapotential measurments  
 A weight of 1 mg of nanoparticles were sonicated for 15 min in 1 ml of distilled water. A 
volume of 75 µl of this solution was diluted in 3 ml of distilled water. DLS and zetapotential 
measurements were taken for this solution. 
1.7.12 ICP (Inductively coupled plasma) Measurements to Determine the Iron Content 
in the Nanoparticles and Sulfur Content on the Nanoparticles due to 
Thiosemicarbazone Coupling 
 Some assumptions were done to calculate the iron content in the Fe/Fe3O4 nanoparticle; 
We assumed the 1 mg of ligand coated Fe/Fe3O4 nanoparticle contains 1 mg of iron. 
 ICP measurements were taken of the dopamine nanoparticle, dopamine peptide 
nanoparticle and all the different coupling ratios of thiosemicarbazone on to the nanoparticles 
(1:10, 1:5, 1:1, 5:1 and 10:1). To determine the iron content approximately 2 mg of the 
nanosystem was weighed and digested in 1 ml of 10 % HCl. Since the concentration was high a 
dilution was done by taking 100 µl of concentrated sample and diluted to 5 ml with 10 % HCl.   
To determine the sulfur content approximately 6 mg of the nanosystem was weighed and 
digested in 3 ml of 10 % HCl. A standard concentration series of iron and sulfur were prepared 
using iron nitrate (Fe(NO3)3 1000 mg/L) and sulfuric acid (H2SO4 1000 mg/ L) in 10 % HCl 
(Table 1.12); 
 
Table 1.12:- Standard concentration series of iron and sulfur. 
Iron concentration 
ppm (mg /L) 
Sulfur concentration 







 The iron content was measured at a wavelength of 259.94 nm and the sulfur content was 




1.7.13 FTIR Identification of Dopamine and Thiosemicarbazone on the Nanoparticle 
FTIR was performed to identify the Dopamine and Thiosemicarbazone attached to the 
nanoparticle. 
FTIR was conducted using the Thermo Scientific Smart Performer Nicolet 380 FT-IR 
using the ZnSe crystal wavelength range of 500-4000 cm
-1
. When performing the FTIR on the 
nanoparticles some spectra were obtained with low noise (190 scans). However, most of the 
nanoparticles generated noise, either due to the scattering effect of the Fe/Fe3O4 nanoparticles, or 
insufficient sample concentration. (Appendix B Figure B.36-42). FTIR was also recorded for 
pure dopamine hydrochloride and thiosemicarbazone analogue for comparison (Figures 1.36, 
1.38, 1.39). 
Therefore, FTIR was also carried out employing a 4 cm
-1
 resolution diffuse reflectance 
FT-IR spectrometer (Cary 630 FTIR) with a wavelength range of 500-4000 nm  to reduce the 
scattering produced by the nanoparticles. First, the background measurement was taken from a 
gold standard block.  Next, the sample was prepared by grinding the nanoparticles (1 mg) with 
potassium bromide (100 mg). This mixture was packed into the sample plate holder for IR 
measurements. 200 scans were taken for each sample (Figure 1.40 and Appendix B Figure B.30-
35).  
 
1.7.14 Extracting Thiosemicarbazone Analogue from the Nanoparticle and Detection 
from HPLC 
 Extraction of thiosemicarbazone was carried out by digesting 3 mg of the nanoparticle in 
1 ml of 10 % HCl. Next, the organic compounds, such as thiosemicarbazone, were extracted into 
1 ml of methylene chloride. The methylene chloride layer was neutralized by 1 ml of 10 %  
sodium bicarbonate. The sample was concentrated by evaporating the solvent. 
 A pure sample of thiosemicarbazone analogue (0.5 mg), diluted in 400 µl of acetonitrile, 
and was used as the standard to determine at which retention time the thiosemicarbazone peak is 
detected.  A volume of 3 µl was injected into the HPLC machine for detection. 
 HPLC was carried out using the LC-6AD Shimadzu liquid chromatography instrument 
with a SPD-20 A UV/Visible detector and Kinetex 5 µ XB- C18 100 A size 250 * 4.6 mm 




The HPLC was conducted using HLPC grade water as the aqueous solvent and acetonitrile as the 
organic solvent. The HLPC was achieved through a gradient of aqueous and organic solvent as 
shown below (Table 1.13); The HLPC can be found in section 1.8.11 in Figures 41-43. 
 
Table 1.13:- Solvent gradient of aqueous and organic solvents for the detection of 
thiosemicarbazone. 
Time (min) Flow A(aq) B(org) Flow rate A % Flow rate B % 
0 1 70 1 0.70 0.30 
30.00 1 20 80 0.20 0.80 
30.01 0 20 80 - - 
 
1.7.15 Transmission Electron Microscopy (TEM) 
 The size of the nanoparticles were determined by TEM, which was performed in the 
Microscopy and Analytical Imaging Laboratory of the University of Kansas. Sample preparation 
and data collection are similarly described in the literature.
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 Samples were prepared by 
suspending the nonoparticles in methylene chloride and agitating in an ultrasonic bath for 15 
minutes. The sample was placed onto copper mesh grid with lacey carbon film. The wet grids 
were allowed to air-dry for several minutes prior to being examined under TEM. The  
nanoparticle size and morphology were examined by bright-field and dark-field transmission 
electron microscopy (TEM) using an FEI Technai G2 transmission electron microscope at an 
electron acceleration voltage of 200 kV. High resolution images were captured using a 
standardized, normative electron dose and a constant defocus value from the carbon-coated 
surfaces.  
1.7.16 Cell Viability Test Measured by MTT Assay 
 Cell viability was tested on both the 4T1 murine breast cancer cell line and a normal 
(healthy) murine fibroblast cell line for the dopamine nanoparticle, dopamine peptide 
nanoparticle and all the different coupling ratios of thiosemicarbazone on to the nanoparticles 
(1:10, 1:5, 1:1, 5:1 and 10:1). The test was done in a 96 well plate. The plate was divided into 
three columns of 4 replicas each for the control, 24 h and 48 h cell viability were tested for 




ratios (Appendix A Figure A.6). The nanoparticle concentrations were made in the growth 
media. 
 The 4T1 murine breast cancer cells were cultured in RPMI (Roswell Park Memorial 
Institute) with 10% FBS (Fetal bovine serum) and 1X penicillin-streptomycin in a 37 °C 
humidified incubator with 5% CO2. After 24 hrs the growth media was removed and 75 µl of 
fresh media was added to the wells. To the 24 h cells 7.5 µl of MTT reagent (3-(4, 5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added and incubated for 4 hrs. 
After 4hrs 75 µl of MTT buffer solution was added to the 24 h wells to dissolve the formazan 
crystals and was incubated overnight. After 48 hrs the same procedure was carried out for the 48 
h wells. The solubilizing reagent was added to the control wells at the time it was added to the 48 
h wells. After incubating overnight the UV was measured at a wavelength range from 550 nm to 
690 nm.  
 The same procedure was carried out for the fibroblast cell line except the growth media 
was DMEM (Dulbecco’s Modified Eagle’s Medium).  
1.7.17 Test for Cell Uptake of Nanoparticles by Prussian Blue Staining 
 Form the results obtained from the cell viability test the cell uptake test was done in only 
the dopamine nanoparticle, dopamine peptide nanoparticle and coupling ratio 5:1 of 
thiosemicarbazone on both the nanopaticles batches with the dopamine ligand and dopamine 
peptide ligand. Nanoparticle dispersions were prepared in the growth media and the 
concentrations tested; 0 µg/ml (control) 5 µg/ ml, 10 µg/ml (Appendix A Figure A.7). 
 Murine breast cancer cells 4T1, were grown in a 24 well plate. The cells were grown in 
RPMI with 10% FBS and 1X penicillin-streptomycin in a 37 °C humidified incubator with 5% 
CO2 for 24 hrs. After 24 hrs the media was removed and 500 µl of the nanoparticle solution was 
added and for the control 500 µl RPMI media was added and was incubated for 24 hrs. 
 After 24 hrs the staining procedure was carried out. The cells were washed twice with 
500 µl RPMI and twice with 1 x PBS (Phosphate buffered saline). Next, 500 µl of 10 % NBF 
(neutral buffered formalin) was added and was allowed to stand for 10 min for fixation to occur. 
The cells were washed three times with 500 µl of 1 x PBS. Next, equal amounts of 4 % 
potassium ferrocyanide and 4 % HCl (500 µl each) were added to the wells. Again, 10 min for 




500 µl distilled water. Next, the cells were stained with 200 µl of nuclear fast red for 5 min and 
washed four times with 500 µl distilled water. The cells were stored in 500 µl PBS and were 







1.8.1 NMR Characterization of Thiosemicarbazone Analogue 
 The NMR studies were performed in an Inova NMR Spectrometer, which operates at 
400MHz frequency (9.7 Tesla). 
1.8.1.1 1H NMR of Hydrazinecarbodithioic acid methylester 
 
1
H NMR (CDCl3-d, δ ppm) 2.66 (s, 3H, CH3), 4.15(s, 2H, NH3
+
 (protonated nitrogen) 
D2O exchangeable) 4.66 (s, 2H, NH2, D2O exchangeable), 8.11 (s, H, NH2
+
CS (protonated 
nitrogen), D2O exchangeable), 8.53 (s, H, NHCS, D2O exchangeable). Appendix B Figure B.1 
and Figure B.2. 
 Melting point of the compound is 79-81
0
C 
1.8.1.2 1H NMR and 13C NMR of N´-(Di-pyridin-2yl-methylene)- 
hydrazinecarbodithioic acid methylester 
 
1
H NMR (CDCl3-d, δ ppm) 2.67 (s, 3H, CH3); 7.52 (s, H, NH);  8.81 (d, H3), 8.62 (d, 
H8), 8.06 (d, H6), 7.84 (m, H5 & 8), 7.73 (d, H7), 7.42 (m, H4), 7.37 (m, H9) of the Ar-H. The 
1
H NMR can be found in Appendix B Figure B.3 and B.4. 
 
13
C NMR (CDCl3-d, δ ppm, J, Hz): 17.70 (CH3); 124.08 (C10), 124.46 (C5), 124.69 
(C12), 127.56 (C7), 137.33 (C6 & 11), 142.55 (C13), 148.30 (C8), 148.62 (C9), 151.31 (C4) of 
the Ar-C; 155.68 (C=N); 202.44 (C=S). The 
13
C NMR can be found in Appendix B Figure B.5. 
 Melting point of the compound is 150-153
0
C 
1.8.2 Characterization of the Peptide by HPLC purification and MS 
 At time 51.62 mins the peptide was detected and shows ~ 90% purity. The HPLC can be 
found in Appendix B Figure B.6. 
 The Mass spectrum was taken by Voyager DE STR High performance matrix-assisted 
laser desorption time-of-flight mass spectrometer (MALDI-TOFMS) equipped with a nitrogen 
laser (337nm). The calculated molecular weight of the oligopeptide 
(CGKRK(D[KLAKLAKKLAKLAK])PLFAERL) is 2923.87 gmol
-1
. The mass spectrometry data 
shows peaks at 2921.77, 2922.77, 2923.77, 2924.77 gmol
-1
. The most abundant peak 2922.77 
gmol
-1




molecular weight of the peptide. The third most abundant peak 2921.77 gmol
-1
 is due to removal 
of 2 hydrogen’s from the peptide. And the least abundant peak 2924.77 gmol
-1
 is due to an 
addition of a hydrogen to the peptide. The mass spectrum can be found in Appendix B Figure 
B.7. 
1.8.3 TEM Images of the Coated Nanoparticles 
 The size of the nanoparticles were determined to be 25-35 nm in size (Appendix B Figure 
B.8). The core/shell structure of Fe/Fe3O4 is clearly discernible. From the TEM it can be 
observed that the bulk Fe(0) phase is crystalline. However, the nanoparticles are not composed of 
a single crystal. The Fe3O4 layer, formed by O2 oxidation after nanoparticle synthesis, however it 
can passivate in aqueous buffers and under air. 
1.8.4 Powder X-ray diffraction (XRD) of the Fe/Fe3O4 Magnetic Nanoparticles 
 The XRD pattern is indicative of the presence of bcc Fe(0) as bulk phase (Figure 1.34). 
Other XRD peaks were not detected when characterizing dopamine-coated Fe/Fe3O4 
nanoparticles (d = 28 +/-2nm). It must be noted that the presence of a surface layer of Fe3O4 






Figure 1.34:- XRD pattern of the synthesized Fe/Fe3O4 nanoparticles after ligand exchange 
oleylamine/ hexadecylamine
. 








1.8.5 X-ray photoelectron spectroscopy (XPS) of the Fe/Fe3O4 Magnetic Nanoparticles 
 XPS is able to reveal the chemical surface composition of the nanoparticles. Typically, it 
can analyze nanoparticles to a depth of 5-10nm. Therefore, it is unable to discern the bulk 
composition. The XPS measurements shown in Figure 1.35 were performed by Dr. Myles 
Ikenberry in the group of Prof. Dr. Keith Hohn, Department of Chemical Engineering, Kansas 
State University. Shown is the surface composition after nanoparticle synthesis and after 
exchange of oleylamine/ hexadecylamine.
 
HCl against dopamine. XPS clearly indicates the 
















Table 1.14:- Iron, oxygen, nitrogen, carbon and chloride content at the catalyst surface, as 
determined by XPS.  
a) Freshly synthesized Fe/Fe3O4 nanoparticles (after air oxidation).  
b) Fe/Fe3O4 nanoparticles after ligand exchange with dopamine. 
 
Sample Fe O N C Cl 
a) Fe/Fe3O4 featuring oleylamine/ 
hexadecylamine
. 
HCl at the surface 
3.4 30.0 2.5 60.8 3.3 
b) dopamine exchanged Fe/Fe3O4 
nanoparticles 
4.5 35.7 10.2 49.3 0.3 
 
 In both nanoparticles, the inorganic surface consisted of Fe3O4. The observed increase in 
nitrogen and oxygen content, together with a decrease in carbon and chlorine content at the 
surface indicates exchange of oleylamine/ hexadecylamine.HCl against dopamine. 
Unfortunately, XPS is only a semiquantitative analysis method. 
1.8.6 UV Measurements of Thiosemicarbazone Analogue Coupling with the Dopamine 
on the Nanoparticle 
 Thiosemicarbazones in DMF exhibit two absorption peaks. The absorption that occurs at 
289-313 nm are due to the π → π* transitions from the aromatic rings. Absorptions at 
wavelengths around 356-396 nm are due to n→π* transitions from the azomethine (C=N) and 
thioamide (C=S) functions overlapped in the same envelope.
83
  
 When looking at the thiosemicarbazone analogue that we have incorporated in our 
research, it also shows two peaks around 282-285 nm and 359-371 nm wavelengths. 
 After reacting with the nanoparticles for four days for the coupling of the 
thiosemicarbazone analogue to the dopamine on either dopamine coated nanoparticles or 
dopamine and dopamine peptide coated nanoparticles the 359-371 nm peak would decrease and 
the 282-285 nm peak would increase. The reason for the decrease in the 359-371 nm peak is that 
after the reaction most of the thiosemicarbazone analogue is coupled with the dopamine and is 




coupled successfully with the dopamine. The increase in the 282-285 nm peak is due to the 
absorption of the Fe/Fe3O4 nanoparticles. Appendix B Figure B.9-13. 
 The concentration of thiosemicarbazone that reacted with the nanoparticles were 
calculated as below (Table 1.15); 
Reaction of thiosemicarbazone analogue 1: 10 dopamine and dopamine peptide coated 
nanoparticle: 
Concentration used                                       =  2.4889 * 10
-5
 mol/L 
Diluted concentration used for UV  
measurements (in reaction mixture              = C1V1 = C2V2 
 without nanoparticles)                                = (2.4889 * 10
-5
) mol/L * 0.5 ml = C2 * 2.5 ml 
                                                                     = 4.9778* 10
-6
 mol/L 
Used the highest absorbance (A)              = 0.432474136 
 (371 nm)                                                   = A= εCl 
                                                                   = ε = A/ Cl 
                                                                            = 0.432474136 / ((4.9778* 10
-6
mol/L)* 1 cm) 





Remaining concentration of                        =   C = A/ εl 




)* 1 cm 
 in the reaction mixture                               = 0.4001245 * 10
-5
 mol/ L 
with nanoparticles at 371 nm                        
                                                                     
Reacted concentration of                            =  (2.4889 * 10
-5
) mol/L – (0.4001245 * 10
-5
) mol/ L 




Percentage of thiosemicarbazone            = ((2.0887 * 10
-5
) mol/L / (2.4889 * 10
-5
) mol/L)* 100% 
 reacted                                                        =  83.92 % 













Table 1.15:- Concentration and percentage to thiosemicarbazone reacted with dopamine in 
dopamine and dopamine peptide coated nanoparticle. 
 
 
1.8.7 DLS Results  
 The mean diameters of the nanoparticles were found as stated below (Table 1.16); (the 
original data are found in Appendix B Figure B.14-21. 
 
Table 1.16:- Mean diameters of the nanoparticles. 
Reaction Ratio Mean Diameter of 
nanoparticles (nm) 
Dopamine-NP 475.6/ 17 = 28 
Peptide-Dopamine-NP-Dopamine  599.0/ 17 = 35 
Peptide-Dopamine NP-Dopamine Thiosemicarbazone (1:10) 505.5/ 17 = 30 
Peptide-Dopamine NP-Dopamine Thiosemicarbazone (1:5) 426.9/ 17 = 25 
Peptide-Dopamine -NP-Dopamine Thiosemicarbazone (1:1) 532.1/ 17 = 31 
Peptide-Dopamine -NP-Dopamine Thiosemicarbazone (5:1) 422.9/ 17 = 25 




Starting concentration of 
thiosemicarbazone analogue 
(mol/L) 






































1.8.8 Zeta Potential Results 
 Zeta potential is the measurement of electrical potential or surface charge of particles. For 
small particles higher zeta potential will give more stability and reduce aggregation. Therefore 
particles with high negative or positive zeta potentials (± 40-60 mV) are stable and would not 
aggregate however particles with low zeta potentials would aggregate or would have moderate 
stability (± 0-40 mV).
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 Since the nanoparticles we made have many N atoms in the ligands 
they should give positive zetapotentials. And since they range from 14 – 38 mV they show 
moderate stability and are expected to show some aggregation. 
 The zeta potential data of the nanoparticles are as below (Table 1.17); (data can be found 
in Appendix B Figure B.22-29). 
 
Table 1.17:- Zeta potentials of the nanoparticles 
Reaction Ratio Zeta potential (mV) 
Dopamine-NP 30.85 
Dopamine-peptide-NP-Dopamine  35.37 
Peptide-Dopamine NP-Dopamine Thiosemicarbazone (1:10) 24.37 
Peptide-Dopamine -NP-Dopamine Thiosemicarbazone (1:5) 14.82 
Peptide-Dopamine -NP-Dopamine Thiosemicarbazone (1:1) 37.13 
Peptide-Dopamine NP-Dopamine Thiosemicarbazone (5:1) 38.70 
Peptide-Dopamine -NP-Dopamine Thiosemicarbazone (10:1) 32.08 
 
1.8.9 ICP (Inductively coupled plasma) Measurements to Determine the Iron Content 
in the Nanoparticles and Sulfur Content on the Nanoparticles due to 
Thiosemicarbazone Coupling 
 From the ICP measurements obtained from the different ratios of the nanoparticles the 
iron content for the nanoparticles ranged from 60-73 %. There was no sulfur detected in the 
nanoparticle coated with dopamine. Sulfur was detected in the nanoparticle that was coated with 
dopamine-peptide ligand due to the sulfur present in the cysteine moiety in the peptide sequence, 
confirming the coupling of the peptide to the dopamine. Sulfur was detected in the different 




Dopamine-NP confirming the coupling of the thiosemicarbazone analogue to the dopamine on 
the nanoparticle. The results obtained are as below (Table 1.18);  
 




per 1mg of NP 
(mg) 
Iron percentage 
per 1mg of NP 
Sulfur content 




1mg of NP 
Dop-NP  0.6109 61 % - - 





0.7063 70.63 % 0.082 * 10
-6
 0.26 % 
Dop-Peptide-NP-
Dop-Thio (1:5) 
0.7265 72.65 % 0.104 * 10
-6
 0.33 % 
Dop-Peptide-NP-
Dop-Thio (1:1) 
0.7276 72.76 % 0.300 * 10
-6
 0.94 % 
Dop-Peptide-NP-
Dop-Thio (5:1) 
0.7285 72.85 % 0.240 * 10
-6
 0.77 % 
Dop-Peptide-NP-
Dop-Thio (10:1) 
0.7195 71.95 % 0.096 * 10
-6
 0.31 % 
Thio-Dop-NP 
(1:10) 
0.7581 75.81 % 0.139 * 10
-6
 0.44 % 
Thio-Dop-NP 
(1:5) 
0.6961 69.61 % 0.156 * 10
-6
 0.50 % 
Thio-Dop-NP 
(1:1) 
0.7841 78.41 % 0.161 * 10
-6
 0.52 % 
Thio-Dop-NP 
(5:1) 
0.8390 83.90 % 0.096 * 10
-6
 0.31 % 
Thio-Dop-NP 
(10:1) 
0.8160 81.60 % 0.094 * 10
-6
 0.30 % 
Dop-NP denotes Dopamine-NP, Peptide-Dop-NP denotes Peptide-Dopamine -NP,  




Calculations to determine the iron and sulfur content in the nanosytems. 
Iron concentration detected by ICP              =  31.29 mgL
-1
 
Original concentration before dilution           =  C1V1 = C2V2 
                                                                        = C1 * 0.1 ml = 31.29 mgL
-1
 * 5 ml 
                                                                        = C1 = 1564.5 mgL
-1
 
Weight of iron in 2.15 mg of NP                   = (1564.5 mg/ 10
3
 ml) *  1 ml 
                                                                       = 1.565 mg 
Weight of iron in 1 mg of NP                        = (1.565 mg/ 2.15 mg) * 1 mg 
                                                                       = 0.7276 mg 
Percentage of iron                                          = (0.7276 mg/ 1 mg) * 100 % 
                                                                       = 72.76 % 
Sulfur content detected by ICP                     = 19.53 mgL
-1
 
Weight in 3 ml of the solution                        = (19.53 mg/ 10
3
 ml) * 3 ml 
                                                                        = 0.05859 mg 
Weight of sulfur in 1 mg of NP                      = (0.05859 mg/ 6.10 mg) * 1 mg 
                                                                        = 0.009604 mg 
Percentage of sulfur                                       = (0.009604 mg/ 1 mg) * 100 % 
                                                                       = 0.96 % 
Moles of sulfur in 1 mg of NP                       = (0.009604 * 10
-3
) g/ 32 gmol
-1 
                                                                       = 0.300 * 10
-6
 mol     
 
1.8.10 FTIR Identification of Dopamine and Thiosemicarbazone on the Nanoparticle 
FTIR signals for aromatic C-C stretching peaks occur between 1335- 1250 cm
-1
. Pure 
dopamine is featuring these peaks at 1344.89 cm
-1
 and 1288.96 cm
-1
. Peaks ranging from 1400-
1650 cm
-1









 for asymmetric stretching. Aromatic C-H 
stretching is between 3000-3120 cm
-1
. This peak is at 3072.77 cm
-1
 for dopamine. The alcoholic 
O-H symmetric and asymmetric stretching vibrations are between 3670-3580 cm
-1
; for dopamine 
they occur at 3340.64 cm
-1
. Alcoholic C-O stretching vibrations are between1200-1000 cm
-1
 for 
dopamine. They are seen at 1077.02-1062.31 cm
-1




are between 2975-2840 cm
-1
. For dopamine this peak is seen at 2931.48 cm
-1
. N-H stretching is 
at 3300-3500 cm
-1
. In dopamine it is seen at 3322.98 cm
-1
. And scissoring of N-H is seen at 
1550-1650 cm
-1
. For dopamine it is seen at 1598.04 cm
-1
. C-O-H symmetric bending and 
asymmetric bending occur at 1261 cm
-1
 and 1320 cm
-1
, respectively. For dopamine they are at 
1259.53 cm
-1




respectively. The spectrum is seen in figure 1.36. The FTIR for 
the dopamine coated on the nanoparticle show similar peaks (Figure 1.37). Therefore, we can 















Figure 1.37:- FTIR of dopamine coated Fe/Fe3O4-nanoparticles. 
 
 The characteristic FTIR peaks for the thiosemicarbazone analogue are the bands in the 
1636 and 1588 cm
−1
 region that may be assigned to the symmetric or asymmetric (C=N) 
vibrations. A peak at 1636.30 cm
-1
 in the thiosemicabazone analogue corresponds to the C=N 
bond. A strong band at 1030-1275 cm
−1
 corresponds to the C=S bond in the thiosemicarbazone 
analogue. It is seen at 1275.57 cm
-1
. The bands that appear in the 1410-1435 cm
−1
 region are due 
to the coupled vibrations of C=S and N-H.  There is a peak present due to these vibrations at 
1412.38 cm
-1
. The band for C=N, which ranges from 3300-3500 cm
-1
, is observed at 3487.82  
cm
-1
. A band for the C-N stretching vibration, which ranges from 1020-1250 cm
-1
, is seen at 
1235.98 cm
-1
. Aromatic C-H stretching is observed at 3037.45 cm
-1
. Alphatic C-H symmetric 




 The FTIR for 






Figure 1.38:- FTIR of Thiosemicarbazone analogue. 
  
 A comparison of dopamine HCl, dopamine coated Fe/Fe3O4-nanoparticles, 
thiosemicarbazone analogue, and the thiosemicarbazone-dopamine coated Fe/Fe3O4-
nanoparticles was performed, which is shown in figure 1.39. Here we can see similar peaks of 
dopamine and thiosemicarbazone, in comparison with dopamine and thiosemicarbazone-
dopamine coated nanoparticles. Therefore, we can determine that the thiosemicarbazone was 
successfully coupled to the nanoparticle. 
 For the peptide-dopamine and thiosemicarbazone-dopamine coated nanoparticle, other 
than the IR peaks for dopamine and thiosemicarbazone, additional peaks for C=O stretching are 
seen around 1700-1600 cm
-1
 and C=N vibrations are seen around 1636-1588 cm
-1
. These peaks 
are much more intense (Figure 1.40).
90
 Therefore, we could determine that the both the peptide 






Figure 1.39:- FTIR comparison for Thiosemicarbazone-Dopamine-NP. 
 






1.8.11 Extracting Thiosemicarbazone Analogue from the Nanoparticle and Detection 
from HPLC 
From the HPLC data we were able to detect the pure thiosemicarbazone analogue at 
13.60 mins (Figure 1.41). The peak area was 84 rel.% as shown in table 1.19.  
 
 
Figure 1.41:- HPLC of Thiosemicarbazone analogue. 
 











  Similarly, detection of the thiosemicarbazone peak was observed in the HPLC of the 
extractions of peptide-dopamine-NP-dopamin-thiosemicarbazone analogue (1:1) at 13.45mins 
(Figure 1.42) and area of 0.07 % (Table1.20) and thiosemicarbazone-dopamine-NP (1:1) also 




Time Area Height Area% 
1 4.002 1281 118 0.014 
2 4.239 2194 142 0.023 
3 5.378 21827 1063 0.232 
4 6.149 40615 1553 0.432 
5 13.606 7966059 380985 84.752 
6 17.631 32156 772 0.342 
7 18.156 52770 1957 0.561 
8 18.983 4152 231 0.044 




The detection times were slightly less than that of the pure thiosemicarbazone analogue. 
This may be because that the concentrations of the thiosemicarbazone was low, or their might 
have been some chemical modification of the analogue, which is less likely, according to the 
FTIR results. The peak areas were also low since concentration of thiosemicarbazone was low. 
 
 
Figure 1.42:- HPLC of Peptide-Dopamine-NP-Dopamin-Thiosemicarbazone analogue (1:1) 
extract. 
 





Time Area Height Area% 
1 3.388 41579 1402 2.776 
2 4.07 102848 1722 6.865 
3 5.558 13170 409 0.879 
4 13.45 1042 52 0.07 
5 17.001 1996 97 0.133 
6 18.322 10597 386 0.707 
7 20.66 83323 1749 5.562 
8 21.725 44029 897 2.939 







Figure 1.43:- HPLC of Thiosemicarbazone-Dopamine-NP (1:1) extract. 
 





Time Area Height Area% 
1 2.677 6804 562 0.414 
2 3.361 45598 1462 2.777 
3 4.055 88210 1790 5.372 
4 5.489 308545 6958 18.79 
5 8.8 1165 87 0.071 
6 9.016 2238 110 0.136 
7 10.842 1556 31 0.095 
8 13.1 1593 64 0.079 
9 18.129 43148 1118 2.628 
10 19.234 2702 144 0.165 
11 20.649 28016 1046 1.706 








1.8.12 Calculation of the Amount of Thiosemicarbazone Analogue coupled to the 
Dopamine on the Nanoparticle                    
 The average size of the nanoparticles used for the delivery of the thiosemocarbazone 
analogue and the therapeutic peptide sequence is 28 +/- 2nm. Furthermore, the average thickness 
of the passivating Fe3O4 layer is 2nm. 
 Therefore, the core of one typical nanoparticles has a diameter of 24nm. This corresponds 

















, which is calculated from the volume 




), minus a nanoparticle with 24nm in 








 leading to a weight of the 
Fe3O4 shell of 2.1689 x 10
-20
 kg. 
 The total weight of a Fe/Fe3O4 core/shell nanoparticle is 7.8691 x 10
-20
 kg. This means 
that in one kg of the material are 1.2798 x 10
19
 nanoparticles or 2.1099 x 10
-5
 mol nanoparticles. 
 What is the maximum number of dopamine at the surface of Fe/Fe3O4 core/shell 
nanoparticles with a diameter of 28nm?  









, as calculated from its 






This data is available from the program 
package Chemdraw 3D (Cambridge Soft Corporation, 1999). The space demand was calculated 
by assuming a sphere for dopamine. This permitted the calculation the area of the circle with the 
same diameter than the sphere. According to this approximation, the surface of a Fe/Fe3O4 
nanoparticle of 28nm in diameter is covered with maximally 2251 dopamine ligands. 
 Assuming that each of the 2251 ligands would be capable of reacting with one 
thiocarbazone precursor (see Appendix A Figure A.5), we would add either 2251 sulfur atoms to 
the outer layer, because each thiocarbazone molecule reacts with the terminal amino group of 
dopamine. The weight of one S atom is 5.3247 x 10
-26 
kg. The weight of 2251 sulfur atoms is 
1.199 x 10
-22 
kg. The weight of the dopamine layer is 4.56 x 10
-22
 kg, assuming that 2251 
dopamine molecules are present in the outer organic layer. Therefore, the weight of one 






 The weight of the chemisorbed sulfur (1.199 x 10
-22 
kg), divided by the weight of one 
nanoparticle (7.9147 x 10
-20
 kg.), yields the factor of 0.0015. This means that coverage with a 
complete layer of thiocarbazone analogues will lead to only 0.15 percent sulfur by weight. The 
sulfur content may increase to 0.24 percent, if the methyl sulfide that is formed as a by-product 
of the coupling reaction, is chemisorbed as well. This calculation also indicates that in the case of 
Dop-Peptide-NP with a sulfur content of 9.68% we have multiple physisorbed layers of peptide 
sequence (CGKRK(D[KLAKLAKKLAKLAK])PLFAERL) around the nanoparticle. 
 Based on this estimate, it is evident that the sulfur content that was determined by ICP 
(see Table 1.18), is slightly too high, by a factor of two to three. This is indicative that 
byproducts of the coupling reactions were trapped by the reactive iron oxide surface during the 
coupling reaction. In conclusion, measuring the sulfur content of the nanoparticles cannot be 
regarded as a feasible strategy to determine the loading degree of the nanoparticles with the 
thiosemicarbazone analogue. It is noteworthy that the coupling efficacy of the thiosemicarbazone 
analogue to dopamine-coated Fe/Fe3O4 core/shell nanoparticles was determined by UV/Vis-
measurements, and the chemical identity of the thiosemicarbazone analogue was confirmed by 
using HPLC. Therefore, the principal composition of these nanoplatforms for drug delivery is 
not in question. 
1.8.13 Cell Viability Test Measured by MTT Assay 
 The cell toxicity of both the 4T1 murine breast cancer cell line and normal murine 
fibroblast cell line of individual nanosystems were incorporated into one graph to determine if 
there was a significant difference in cell toxicity towards the cancer cell line than the normal cell 
line. The data can also show if the nanosystem is able to specifically target the cancer cells vs. 
the normal cells (Table 1.22). The data are found in Appendix B Figure B.41-52. 
 
The cell toxicity data were analyzed and plotted as below; 
1. For each well  the UV690 values were subtracted from the UV540 values. 
2. The mean UV values were calculated for every test sample concentration. 
3. The mean UV values of the blanks were calculated.  
4. The sample and solvent control UV’s were corrected as below: 




5. Relative inhibition activity is expressed as percent of solvent control: 
              % inhibition = 100 -   Corrected mean UVabs sample x 100  
                                                  Corrected mean UVabs solvent controls) 
6. The % inhibition of activity against the test compound concentration was plotted to 
obtain the cell toxicity curve. 
 
 Notable difference in toxicity can be seen in the 5:1 ratio of both the dopamine-peptide-
NP-dopamine-thiosemicarbazone and NP-dopamne-thiosemicarbazone nanoparticle systems. 
From this observation we can say that the ratio of thiosemicarbazone incorporated in the 
nanosystem is of importance when considering therapeutic activity.  
 Most of the other nanosystems showed close or similar toxicity in both cell lines. In some 
ratios the 48 h cell toxicity would be more in the cancer cell line. 
  
 The IC50 values were calculated by the equation below; 
 
                    Log (% inhibition / (100 -% inhibition)) vs. Concentration 
 























IC50 Values for  
4T1 cell line (ug/ml) 
IC50 Values for Fibroblast cell 
line (healthy cells) (ug/ml) 
Dop-NP  71 (± 0.02) 50 (± 0.02) 
Dop-Peptide-NP 37 (± 0.05) 17 (± 0.11) 
Peptide-Dop--NP-Dop-Thio 
(1:10) 
50 (± 0.06) 82.5 (± 0.02) 
Peptide-Dop-NP-Dop-Thio 
(1:5) 
45 (± 0.02) ~  
Peptide-Dop-NP-Dop-Thio 
(1:1) 
44 (± 0.06) 47 (± 0.03) 
Peptide-Dop--NP-Dop-Thio 
(5:1) 
36 (± 0.03) 80 (± 0.03) 
Peptide-Dop-NP-Dop-Thio 
(10:1) 
37 (± 0.01) 43 (± 0.01) 
Thio-Dop-NP (1:10) 70 (± 0.05) 92 (± 0.01) 
Thio-Dop-NP (1:5) 80 (± 0.02) ~  
Thio-Dop-NP (1:1) 80 (± 0.06) ~  
Thio-Dop-NP (5:1) 32.5 (± 0.06) ~  
Thio-Dop-NP (10:1) 67 (± 0.03) 80 (± 0.02) 
 
IC50 values given with standard errors. 
~ denotes that the IC50 is more than 100 µg/ml.  
Dop-NP denotes Dopamine-NP, Peptide-Dop-NP denotes Peptide-Dopamine -NP-Dopamine,  








1.8.14 Cell Uptake of Nanoparticles by Prussian Blue Staining 
According to the cell toxicity experiment only the nanoparticle systems;  
1. Dopamine-NP 
2. Peptide-Dopamine-NP-Dopamine 
3. Peptide-Dopamine -NP-Dopamine-Thiosemicarbazone (5:1) 
4. Thiosemicarbazone-Dopamine-NP (5:1) 
 Were tested for the cell uptake experiment. 
All nanosystems showed cell uptake. The nanoparticles, which are blue in color after staining, 
have surrounded the nucleus confirming that the nanoparticles are taken up by endocytosis. 








  We were successful in exchanging the dopamine-peptide ligand onto the nanoparticles 
and this was confirmed by the sulfur content obtained by the ICP experiments, which is due to 
the cysteine moiety in the peptide sequence. The usual method to attach ligands onto the 
nanoparticle is by first synthesizing the ligand and next exchanging the ligand with the existing 
ligands on the nanoparticle. However we used a non-conventional method where we have 
coupled thiosemicarbazone analogue onto the free dopamine on the nanoparticle, where the free 
dopamine ligand has already been exchanged to the nanoparticle. This method was done since it 
was impossible to synthesize the dopamine-thiosemicarbazone analogue in the required purity, in 
spite of attempting numerous synthetic methods and purification methods. The result was, 
principally, always the same: the yield would be low and the compound was impossible to 
purify. In sharp contrast, coupling of the thiosemicarbazone analogue with the dopamine on the 
nanoparticle was confirmed by the detection of sulfur content obtained by the ICP experiments, 
therefore by using the unconventional method we were successful in coupling the 
thiosemicarbazone iron chelator onto the nanoparticle. One would assume that the sulfur content 
of the nanoparticles containing both the peptide and thiosemicarbazone analogue would be 
higher than the nanoparticle with just the peptide sequence. However, after coupling with 
thiosemicarbazone, the sulfur content was lower than that of the nanoparticle with just the 
peptide sequence. This may be due the fact that physisorption of the dopamine peptide ligand 
had occurred instead of chemisorption. Therefore, when the coupling reaction with the 
thiosemicarbazone is performed, the physisorbed peptide is competitively removed. Another 
possibility is the degradation of the peptide during the reaction, although we have not obtained 
experimental evidence in favor of this assumption. 
 According to the DLS and zeta potential experiments we can see that the nanosystems are 
of preferable size needed for therapeutic activity. From the cell toxicity experiments we were 
able to determine that the ratio at which thiosemicarbazone was coupled, was of importance 
since only the 5:1 ratio was successful in obtaining a significant difference in the toxicity of the 
4T1 cancer cells than the normal fibroblast cells. The other nanosystems showed very similar 
toxicity to the cancer cells and their control group. From the IC50 values we can see that all the 




fibroblast cell line. This shows that the nanosystem is more effective in the cancer cell line than 
the healthy cell line. Furthermore the lowest IC50 values are shown in both the 5:1 ratio 
nanosystems further demonstrating that this ratio is ideal for therapeutic use. From the prussian 
blue staining experiment we were able to determine that the nanosystem were successfully taken 
up by the 4T1 cells confirming the that the endocytic pathway is the main uptake pathway.  
 According to our calculations (see chapter 1.8.12), the weight of one dopamine-coated 
Fe/Fe3O4 core/shell nanoparticles of 28 nm in diameter is 7.8691 x 10
-20
 kg. Considering that the 
molecular mass of the thiosemicarbazone analogue is 276 g/mol, the weight of one molecule is 
4.6329 x 10
-25
 kg. This leads to a weight ratio of thiosemicarbazone analogue and nanoparticle of 
approx. 1 to 169,853. 
 The nanoplatform showed the highest efficacy against 4T1 cells when reacting with 5 
thiosemicarbazone analogue per surface dopamine. We have determined by means of UV/Vis-
measurements (see 1.8.6) that 38 percent of the thiocarbazone precursor has reacted. This means 
that we have complete surface coverage, plus a second layer of physisorbed thiocarbazone. This 
surface coverage showed the highest efficacy in killing highly metastatic cancer cells          
(IC50= 36 µg/mol), while being significantly less toxic against the healthy control cell line 
(fibroblast cell line, IC50= 80 µg/mol). At an attempted loading of 10:1 (27% conversion), we 
have a complete chemisorbed layer and a larger physisorbed layer, consisting of approx. 1.7 
times the amount of thiocarbazone that was bound to dopamine. This higher loading caused 
toxicity against cancer cells and healthy cells alike. Therefore, it is our conclusion that 
synthesizing a monolayer of thiosemicarbazone analogue around the thiosemicarbazone 
analogue is most favorable with respect to minimizing the collateral damage to healthy cells. At 
this optimal ratio (monolayer), the IC50 Value for 4T1 cell line is 36 (± 0.03) g/ mol. However, 
the required mass of the therapeutic nanoplatform contains the Fe/Fe3O4 iron core. With respect 
to the thiosemicarbazone analogue, is at by a factor of 30 lower, considering that the drug is only 
surface bound. This means that the thiosemicarbazone analogue synthesized at the surface of the 
Fe/Fe3O4 nanoparticles is active in the low micromolar range. 
 The results we obtained do not justify our original hypothesis that the combination of 
both peptide sequence and iron chelators would cause a synergistic effect increasing the 
cytotoxicity when treating cancer. However, they lead the way towards a novel strategy in 




normal cells. This is of great importance, because only approx. 10 percent of a nanoparticle-
based drug is able to reach the tumor. 
 Future work will be performed to clarify our hypothesis by synthesizing the nanosystem 
in the reverse manner, by first coupling the thiosemicarbazone analogue to the dopamine coated 
nanoparticle and then exchanging ligands with the dopamine-peptide ligand. Other studies can be 
performed to determine the redox activity and ROS activity of the nanosystem by conducting 
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Chapter 2 - Using Cell Delivered Nanoparticles to Cause Local 
Hyperthermia and Increasing Survival in a Murine Metastatic 
Pancreatic Cancer Model 
2.1 Abstract 
Localized hyperthermia using magnetic nanoparticles to absorb alternating magnetic field 
(AMF) energy has been shown to be a potential cancer treatment.  Here, we demonstrate a 
system that uses tumor homing cells to actively carry iron/iron oxide nanoparticles into tumor 
tissue for AMF treatment.  Paramagnetic iron/iron oxide nanoparticles were synthesized and 
loaded into RAW264.7 cells (mouse monocyte/macrophage like cells, Mo/Ma), that we have 
shown to be tumor homing cells.  A murine model of disseminated peritoneal pancreatic cancer 
was then generated by intraperitoneal (i.p.) injection of Pan02 cells.  After tumor development, 
Mo/Ma loaded with iron/iron oxide nanoparticles were injected i.p. and allowed to migrate into 
the tumor.  Three days after injection, mice were exposed to an alternating magnetic field for 
twenty minutes to cause the cell-delivered nanoparticles to generate heat.  This treatment 
regimen was repeated three times. A survival study demonstrated that this system can 
significantly increase survival in a murine pancreatic cancer model, with an average post-tumor 
insertion life expectancy increase of 31%.  This system has the potential to become a useful 
method for specifically and actively delivering nanoparticles for local hyperthermia treatment of 
cancer. (This work has already been published in; International Journal of Nanomedicine ,2012, 






Pancreatic cancer is known to be one of the most lethal forms of cancer, with five year 
survival rates of less than 5%.
1
 Discovering new methods for successfully treating pancreatic 
cancer is a virtual necessity for combating this disease.   
 Hyperthermia has been a cancer therapy method for decades.  Tumors have shown 
increased susceptibility to thermal toxicity versus healthy tissue due to their increased rate of cell 
cycling, increased hypoxia, poor fluid exchange and increased acidity.
2, 3
 Whole body 
hyperthermia is an easy way to take advantage of this differential toxicity to treat cancer.   
Unfortunately, ‘extreme’ whole body hyperthermia (>41.5°C), which elevates core temperatures 
to the level where direct thermal toxicity is observed, can cause severe side effects, which may 
limit its usefulness.
4-8
 Fever-level whole body hyperthermia (~39-41°C) can mitigate many of 
these side effects and has potential to be an effective cancer treatment, but this lower heat level is 




 Generating localized ‘extreme’ hyperthermia at the cancer site could alleviate many of 
the side effects associated with whole body hyperthermia while still taking advantage of the 
thermal susceptibility of tumors. One particularly promising method for generating localized 
hyperthermia is using magnetic nanoparticles (MNP) to absorb energy from alternating magnetic 
fields (AMF) and turn this energy into heat.  This method is promising because the body is 
extremely permeable to AMF, which produce no known effects in the body.  Fe/Fe3O4 MNP also 
have been shown to be very safe with very little interaction in the body.  Only at the location of 
the MNP is the AMF energy absorbed and converted to heat.  By specifically delivering the 
MNP to the tumor site, localized hyperthermia can be created.
11-13
  
 Using MNP for generating localized hyperthermia has proven successful; there are 
several clinical trials using injectable MNP combined with AMF for tumor treatment.  Current 
methods of delivering MNP for localized hyperthermia depend on direct injection of milligram 
amounts of MNP into the tumor site.
14-23
  
 Although practical for easily accessible, primary tumors, this limits the usefulness of 
MNP-generated localized hyperthermia for deep tumors, locally or systemically metastatic 




cytotherapy.  Cytotherapy utilizes delivery cells, such as stem cells or other cells, to carry a 
payload into the tumor site.
24-32
  
 Cytotherapy-directed hyperthermia has been successfully demonstrated to attenuate 
mouse melanomas. Monocytes and macrophages are known to infiltrate tumor sites and thus 
could act as cytotherapeutic drug delivery vehicles.
33-35
 Several recent studies have demonstrated 
the feasibility of delivering therapy to tumors using monocytes or macrophages, including 
targeting liposomes containing fluorescent markers to gastric tumor
36
, targeting adenovirus to 
prostate tumors
37
, and targeting gold nanoshells to gliomas
38
.   
 Here we demonstrate a system that uses monocyte-like tumor homing cells to deliver 
MNP directly into the tumor tissue. We have demonstrated that RAW264.7 cells 
(monocyte/macrophage-like cells, Mo/Ma, ATCC TIB-71) specifically infiltrate pancreatic 
tumors when injected intraperitoneally (i.p.) without infiltrating other organs.  These cells were 
loaded with MNP in order to deliver the MNP specifically to the tumor for localized 
hyperthermia.  To test this system, a murine model of disseminated peritoneal carcinomatosis of 
the pancreas was generated by injecting Pan02 cells i.p. into C57BL/6 mice.
39
 MNP loaded 
Mo/Ma were then injected and allowed to infiltrate the tumor tissue.  Three days after Mo/Ma 
injection, mice were treated with AMF.  This treatment system significantly increased the 
survival time of mice bearing i.p. pancreatic tumors, with an average lifespan increase post 






2.3.1 Iron/ Iron Oxide Nanoparticles 
The development of nanotechnology has dramatically increased in the last couple of 
decades. Scientific studies have lead to the understanding of the behavior of the nanoparticles 
such as stability, control of surfactants, particle size, suitable materials to produce nanoparticles 
and physical behavior. These studies provide a good insight that will lead to nanoparticles that 
can be tailored accordingly for biomedical applications and diagnostics.
40, 41
 
Iron/iron oxide (Fe/Fe3O4) nanoparticles have been used for about 40 years for various 
medical applications. The physical and chemical properties of these nanoparticles do not contain 
the characteristics of either the atom or the bulk counterparts and exhibit superpaprmagnetic 
properties. These superparamagnetic or ferromagnetic nanoparticles can be used for several 
biomedical applications due to their specific mesoscopic physical, chemical, thermal and 
mechanical properties and with proper surface chemistry. The biomedical applications 
include;
40,41 
 Magnetic resonance imaging (MRI) 
 Drug delivery 
 Hyperthermia 
 Tissue repair 
 Immunoassays 
 Detoxification of biological fluids 
 Cell separation 
 Magnetofection 
 
In order to achieve these in vivo applications they need to have a small particle size 
smaller that 100 nm, a narrow particle size distribution, they should have a surface coating which 
is nontoxic and biocompatible and should have high magnetization values.
41
 
2.3.2 Magnetic Iron/ Iron Oxide Nanoparticles for Biomedical Applications 
There are several types of magnetic Fe/Fe3O4 nanoparticles that have been studied and 




is mostly used since it is more biocompatible than maghemite. Magnetite forms a fcc closed 
packing cubic inverse spinel structure. Here the iron cations are occupied at the interstitial 
tetrahedral and octahedral sites. It is a half- metallic material and has quantum size effects and a 
large surface area changing its magnetic properties into superparamagnetic properties since a 
particle is considered as a single magnetic domain.
40, 42
 
The synthesis of nanoparticles is challenging in producing nanoparticles with specific 
size and shape. There are many methods to synthesize nanoparticles such as Ostwald ripening, 
water-in-oil microemulsion method. In the synthesis of nanoparticles, there are two stages 
involved where first when the concentration of the species reaches its critical supersaturation a 
short burst of nucleation occurs, next, a slow growth of nuclei occurs by the diffusion of solutes 




The size and shape of the nanoparticles can be controlled by adjusting the pH, ionic 





 ratio used in the reaction. The use of surface modifiers is crucial to stabilize the 
Fe/Fe3O4 nanoparticles from aggregation in both biological medium and magnetic field. This can 




Stabilizers that can be used are;
40, 41 
 Carboxylates, phosphates, which are known to bind to the surface of magnetites. 
 Inorganic material such as silica or gold can be used to coat the nanoparticles. They can 
also help in binding other biological ligands. 
 Polymer stabilizers such as dextran, polyethylene glycol, polyvinyl alcohol and chitosan. 
 Long chain surfactants such as oleic acid, stearic acid. 
 
 To prevent the Fe/Fe3O4 nanoparticles from oxidation and agglomeration and inert gas 
such as argon or nitrogen can be bubbled through the reaction solution during the synthesis. It 










Figure 2.1:- Stabilization of Iron/ Iron oxide nanoparticles coated with stabilizers.
40
 
2.3.2.1 Drug Delivery 
Magnetic nanoparticles show promising applications in drug delivery. The surface or the 
nanoparticles can be modified such that drugs and various biological ligands (e.g. tumor 
targeting peptides, proapoptotic peptides, DNA, RNA and antibodies), which target tumors or 
specific organs. These surface modified nanoparticles are able to reduce drug doses and side 
effects to normal cells, as well as the costs associated with drug treatment. This is most important 
in cancer treatment since therapeutic nanoplatforms would specifically target the cancer cells and 
release their payload into the cells.
40,41
 
Fe/Fe3O4 nanoparticles that are not surface modified have a short blood half-life of 




However surface modified Fe/Fe3O4 nanoparticles have long blood of hours (48 hrs) circulating 
times and are useful for imaging vascular compartment (magnetic resonance angiography), 
lymph nodes, perfusion imaging, receptor imaging and target specific imaging.
40 
These magnetic nanoparticles can be magnetically controlled in the vascular by an 
external magnetic field. Therefore, they can be magnetically guided and can be retained into a 
specific location. For instance, magnetic nanoparticles were retained at the tumor site, where it 
can release its payload and carry out its activity.
40
 
The internalization of nanoparticles into cells depends on their size. Nanoparticles 
administered which range from 10 nm to 100 nm are the ideal size for intravenous injection. 
They show long circulation times and are small enough to avoid rapid clearance by the 
reticuloendothelial system. They can also penetrate through capillaries prior to systemic 
clearance and are the most effective particle size for biological application. Particles larger than 
200 nm in diameter are removed by the spleen by mechanical filtration and are ultimately 
removed by phagocyte system reducing its blood circulation time. Particles with diameters less 
than 10 nm are rapidly removed by extravasation and renal clearance. . These effects greatly 
reduce their blood circulation time.
40, 41 
Since cancer cells proliferate at a higher ratio than normal cells they need to meet the 
high demand of nutrients. Therefore, new blood vessels have to be formed when the cancer 
grows. This process is called angiogenesis. These blood vessels are leaky with average pore size 
of 100-600 nm. The leaky pores can facilitate nanoparticles to diffuse into the cancer tissues 
thereby making it a good carrier for drugs into cancer cells.
43
 
2.3.2.2 Magnetic Resonance Imaging (MRI) 
The use of superparamagnetic Fe/Fe3O4 nanoparticles (SPIO) as contrasting agents play 
an important role for MRI. SPIO tagged with certain specific homing peptides or antibodies 
allows early detection of pathological tissues, such as the differentiation of cancerous tissues 
form normal healthy tissues (Figure 2.2). MRI can also be used to track cells in the body that 
have been tagged with SPIO and can also be used to detect apoptosis where the MR image 









Figure 2.2:- MRI Using Fe/Fe3O4-NPs, Delivered by NPC cells, B16F10 Lung Tumors in  
Black Mice. 
                     A: Control  
                     B: Accumulation of the Fe/Fe3O4/stealth nanoparticles in lung melanomas 
All results were obtained in an 400MHz at the Oklahoma Medical Research Foundation Nuclear 
Magnetic Resonance Core. These figures were adopted form Dr. Thilani Samarakoon’s thesis, 
Kansas State University, 2010 
 
The contrasting ability of SPIO is due to their high transverse relaxivity. In a magnetic 
fluid, ferromagnetic particles dispersed in a liquid, which forms a colloid. Each crystal in the 
colloid suspension is small in size and is fully magnetized forming nanomagnets and is 
composed of single domains. When a SPIO is subjected to an external magnetic field, the entire 
crystal aligns with the applied field due to the single crystal nature, which enhances the magnetic 
flux. Changes in MRI signal are produced through disturbances caused in the local magnetic 
field induced by large magnetic moments causing rapid dephasing of surrounding protons.
40, 41, 44
 
The MRI contrast relies on the relaxation of these crystals back to equilibrium. There are 
two relaxation processors involved, which are commonly described as Néel relaxation and 
Brownian relaxation (Figure 2.3).  
The Néel relaxation occurs in sufficiently small nanoparticles and is defined as the time 
taken for the particles to return back to equilibrium after perturbation. Brownian relaxation is 
detected in larger particles and characterizes the viscous rotation of the entire particle. Therefore 
















The use of heat (hyperthermia) is a therapeutic procedure to increase the temperature of a 
particular area of the body with cancer. This treatment method has been practiced for centuries. 
Heating methods that were used to destroy tumors included hot irons which was stated by 
Hippocrate (460-370 BC), later methods included the use of a hot water bath, pyrogens (bacterial 
toxins), perfusion heating and more recently high frequency radiation and magnetic fluid 
hyperthermia.
 40, 41, 45, 46, 
 
It is known that tumor cells are more sensitive to heat than normal healthy cells. When 
the temperature is increased more than 43
0
C tumor cells are destroyed. However normal cells 
survive at higher temperatures. Therefore by exposing tumor cells to increased temperatures the 
tumor tissue can be destroyed by hyperthermia.
 40, 41
 
The rationale behind this theory is that the microenvironment of cancers are chaotic 









The effectiveness of hyperthermia depends on the temperature and the exposure time 
used. The exposure time can be halved with each 1
0
C increase at temperatures above 42.5-43
0
C. 
Normal cells exposed to temperatures up to 44
0
C for 1 h are undamaged however, the nervous 





The main mechanism of cancer cell death is due to protein denaturing at 
temperatures more than 40
0
C. The various cellular damages that occur through hyperthermia are 
the membranes, cytoskeleton, synthesis of macromolecules and DNA repair.
45, 46
 
After the cells are exposed to heat they undergo a phenomenon called thermo resistance 
(thermotolerance) for about 24-48 hrs. This occurs due to upregulation of certain proteins such as 
heat- shock proteins (HSP). These HSPs are a heterogeneous group of molecular chaperones and 
are subdivided into HSP 60, HSP 70, HSP 90 and HSP 100. They prevent the interaction of 
denatured proteins with other proteins, which would have caused loss of function in the other 




2.4.1 Methods to induce hyperthermia 
 Currently in clinical applications of hyperthermia the optimum temperature distribution is 
still not known. It is challenging to increase temperatures above the systemic temperature 
37.5
0
C.  Temperature increase ranges around 39.5 
0
C to 40.5 
0
C and limited homogeneity is 
observed due to the physical and physiological characteristics such as electrical tissue 
boundaries, local perfusion variations and perfusion regulations. It is observed that a temperature 
of at least 42
0




 There are three main methods that are used to maintain hyperthermia; 
1. Local hyperthermia 
2. Regional hyperthermia 





2.4.1.1 Local hyperthermia 
This method is aimed to be used for superficial tumors. The types of methods that local 
hyperthermia can be applied are external, intraluminal or interstitial methods. Heating is done by 
the use of antennas or applicators, which emit electromagnetic energy such as microwaves or 
radio waves or ultrasound energy. This method of heating system has several components 
(Figure 2.4) as a water bolus to ensure the electromagnetic coupling of the applicator to the 
tissue. The temperature of the tumor can be controlled by the output of the power generator or by 
changing the position of the applicator. The therapeutic depth reaches only several centimeters 
and is limited in areas such as the head and neck due to the irregular surface. There are some 
applicators that are commercially available that have a frequency of 150- 430 MHz having an 
emitting diameter of 15 cm and show about 3 cm of therapeutic depth.
45, 46
 
2.4.1.2 Regional hyperthermia 
This method of hyperthermia is done for deep-seated tumors such as tumors in the 
abdomen or pelvic area. Regional hyperthermia system uses several antennas. One of the mostly 
used regional hyperthermia applicators is the Sigma-60 applicator (Figure 2.5) it has 4 dipole 
antenna pairs that are situated around the patient for heating. Each pair of antennas can be 
controlled by changing the phase and amplitude of the energy used. However monitoring of 
heating should be done to ensure proper specific absorption rate (SAR) distribution.
45
 
2.4.1.3 Whole body hyperthermia 
This method of heating is done for patients with metastatic cancer. Whole body 
hyperthermia (WBH) is done under strong analgesics and sedation or general anesthesia. It is 
known to achieve a maximum heating temperature of 42
0
C for 1 h with acceptable side effects. 
The basal metabolic rate can be doubled at a temperature of 42
0
C in a patient weighing 70 kg 
(basal metabolic rate is 85W at 37 
0
C). It would take 180 min to reach 42 
0
C from 37.5 
0
C of 
body temperature. The current WBH systems (Figure 2.6) that are clinically used have heating 
times of 60-90 min. A heating system that is currently used is the Aquatherm system (Figure 2.6) 
which has an isolated- moisture- saturated chamber containing tubes with water that flows at a 
temperature of 50-60
0
C in the interior of the system where the patient lies. Long wavelength 




disorders, changes in the coagulation system, permeability of the capillary endothelium. Fluid 




Figure 2.4:- Scheme for a local hyperthermia system.
45 








Figure 2.6:- Whole body hyperthermia systems  
A. Iratherm system B. Aquatherm system.2, 45 
 
2.4.1.4 Heating by magnetic nanoparticles 
A much more recent approach to induce interstitial hyperthermia in tumors can be done 
by injecting a ferrofluid (fluid containing Fe/Fe3O4 nanoparticles) into the tumor and expose it to 
an alternating magnetic field. This is a method that can be used to have better control over 
hyperthermia at the tumor location.
46 
Ferrofluids of superparamagnetic or ferromagnetic Fe/Fe3O4 nanoparticles when 
subjected to an alternating magnetic field they start to spin (Figure 2.7), generating heat. 
Therefore, by embedding magnetic particles into the tumor site and exposing it to and alternating 
magnetic field heat will be generated depending on magnetic properties of the material, the 
strength of the magnetic field applied, frequency of oscillations, and cooling capacity of the 








Figure 2.7:- Heat generation by superparamagnetic Fe/Fe3O4 nanoparticles when 
                       subjected to an alternating magnetic field. 
 
 The magnetic energy of the nanoparticles shows a synoidal wave when subjected to an 












The specific absorption rate (SAR) is the parameter that determines heating of the tissues. 
It is defined as; “The rate of which electromagnetic energy is absorbed by a unit mass of 
biological material”. Its units are in calories per kilogram. SAR is proportional to the increase in 
temperature (ΔT/ Δt) and is calculated by the equation below (Equation 6). 
 
           
 
                                                                                                                                                                                                                                   
Where; 
           P   =   Electromagnetic wave power absorbed by the sample 
          me   =   Mass of the sample 
          Ce  =   Specific heat capacity of the sample 
 
The use of low-frequency magnetic wave ranging around 100 kHz to 400 kHz is 
appropriate to be exposed to tissues containing ferrofluids. This specific range is used to control 
the energy released into the tissue, if not inhomogeneous heating will occur.
41
 
2.4.1.4.1 Magnetic heating apparatus used in our study 
 A heating apparatus was constructed by converting a 10 kW commercial inductive heater 
into an AMF generating apparatus (Figure 2.8). Here a copper coil was used to produce 145 kHz 
of alternating magnetic field. The mice were placed through the copper coil for heating. 
 





2.5 Monocyte/ Macrophage like Cells as a Drug Delivery Vehicle 
Monocytes and macrophages are mononuclear phagocytic cells that represent the 
mononuclear phagocyte system (MPS) and are derived from the bone marrow and yolk sac 
progenitors (Figure 2.10). They are also synthesized by the extra-medullary hematopoiesis in the 




Monocytes and macrophages are essential for innate immune functions, support of 
adaptive immunity and tissue homeostasis. It is known that monocytes are recruited to site of 
inflammation for pathogen clearance, tissue repair and wound healing that restores homeostasis. 
It is now understood that chronic inflammation may be the underlying cause of cancer. At these 
inflammated sites monocytes are recruited and differentiated into mature inflammatory 
macrophages which intern produces chemokines and cytokines. These chemokines and cytokines 
are receptors expressed on the monocytes, which lead to further recruitment of monocytes and 
macrophages and enhances the inflammation in the cancer site. There are several surface markers 
and receptors or so called as receptor ligand pairs that recruit monocytes and macrophages into 








Figure 2.10:- Origin of monocytes and macrophages in steady-state and disease conditions. 
                    Monocytes (Mo), hematopoietic stem cells (HSC), common myeloid progenitors 
(CMP), granulocyte macrophage progenitors (GMP), monocyte/macrophage dendritic cell 
progenitors (MDP), “classical” Ly6Chigh and “non-classical” Ly6Clow monocytes, monocyte-
derived macrophages (Mo-MΦ), monocyte derived dendritic cells (Mo-DCs), yolk sac-derived 
macrophages (YS-MΦ), monocytic -myeloid-derived suppressor cells (M-MDSCs), 
immunosuppressive tumor-associated macrophages (TAMs).
47 
 
The method by which monocytes are infiltrated into tumor tissue is first by the interaction 
of monocytes CD62L receptor on the monocyte to its ligand expressed on the inflamed 
endothelial cells. The CD62L is highly efficient in tethering monocytes that are flowing in the 








Figure 2.11:- Mechanism of monocyte recruitment and exravasation.
49 
 
Drugs can be delivered to inflamed site in cancer by taking advantage of the monocytes 
ability to migrate to site of inflammation. Monocytes and macrophages can be used as vehicles to 
transport superparamagnetic Fe/Fe3O4 nanoparticles to cancer sites and facilitate the uptake of 
the nanoparticle to achieve their therapeutic effect. The mechanism by which the nanoparticles 
are incorporated into the monocytes and macrophages is by their ability to uptake or in other 
words to be able to phagocyte foreign particles through opsonization. Opsonization is the process 
where foreign bodies are marked by antigens, which allows the recognition for the monocytes or 
macrophages to facilitate phagocytosis. It is found that charged particles are taken up more than 
neutral particle and among the positively charged particles are able to accumulate more than 
negative particles. Due to the small size and stable nature of nanoparticles they can be packed 
within monocytes and macrophages for drug transport.
48-51
 
This monocyte / macrophage mamoparticle delivery system offers several advantages 
such as improved targeted drug transport to inflamed site, prolong plasma half life and increase 
in therapeutic efficacy, the dose amount can be reduced and reduction in drug immunogenicity 
and cytoxicity profiles can be achieved. There are some factors that are needed to be considered 
when cells are used as carriers for drugs, which are, that the loaded drug should not be released 




cell carriers loaded with the drugs should not diminish its ability to migrate to the target site and 







2.6 Methods  
2.6.1 Cell Culture 
RAW264.7 cells were cultured in RPMI medium containing 10% FBS, with 100 g/mL 
G418 and 100 g/ml hygromycin in a 37°C humidified incubator with 5% CO2.  Pan02 cells 
were cultured in RPMI with 10% FBS and 1X penicillin-streptomycin in a 37 °C humidified 
incubator with 5% CO2. 
2.6.2 Synthesis of Nanoparticles 
The ligand 3-(3,4-dihydroxyphenethylcarbamoyl)propanoic acid tetraethylene glycol 
ester (ligand1) (Appendix A Figure A.8 A) was synthesized from 3-(3,4-dihydroxyphenethyl 
carbamoyl)propanoic acid, (3-(3,4-dihydroxyphenethylcarbamoyl)propanoic acid was 
synthesized by multi-step protection and de-protection of dopamine hydrochloride, followed by 
reacting with succinic anhydride), EDC coupling with tetraethylene glycol and Pd/C catalyzed 
hydrogenation de-protecting benzyl group according to published methods.
52, 53, 54
 50 mg of 
ligand 1 was dissolved in 10 mL THF, and 20 mg Fe/Fe3O4 nanoparticles (NanoScale) were 
added.  After sonicating for 60 minutes, the nanoparticles were precipitated by centrifugation 
(10000 rpm) and washed with 3.0 mL of THF for 10 washing-centrifugation/re-dispersion 
cycles. After drying in high vacuum, 18 mg of surface-modified nanoparticles were obtained. 
TEM imaging showed that the resulting nanoparticles were rod-like in shape (Appendix A 
Figure A.8 B, C, D). 
The following procedures were adopted from Beistein J. Nanotechnology, Wang et al.  
2.6.2.1 Synthesis of Boc Protected Dopamine  
 
 Dopamine (310 mg, 1.63 mmol) was stirred in methanol (8 mL) under N2 for 5 minutes. 




The reaction was carried out for 12 hrs under N2. Next the solvent was removed under reduced 
pressure. The product was dissolved in 40 mL CH2Cl2 and washed with 1 N HCl (3×5 mL) and 
brine (5 mL). The organic layer was dried with anhydrous Na2SO4. The organic phase was 
filtered and was kept at −5 °C for 3 hours. The Boc protected dopamine precipitated out as a 
white product and was collected by filtration. (98% yield). 
2.6.2.2 Synthesis of Benzyl Protected Boc-Dopamine 
 
 
 Boc-protected dopamine (3.47 g) was dissolved in 100 mL DMF. To this solution K2CO3 
(12.6 g) was added and was reacted under N2. Next benzyl bromide (4.69 g, 2 eq.) was added 
drop wise. The reaction was reacted in dark conditions at room temperature for 24 hours. 
Filtration of the solid was done through a short pad of celite and the filter-cake was washed with 
ether (3×100 mL). The filtrate was washed with ice-water (3×50 mL) and brine (15 mL). The 
organic layer was dried with anhydrous Na2SO4 and concentrated to 150 mL. The product was 
formed after setting at −5 °C for 5 hours. The white precipitate was collected by vacuum 
filtration. (93% yield). 







Benzyl and Boc protected-dopamine (4.3g) was stirred in 150 mL 5% TFA CH2Cl2 
solution and at room temperature for 5 hours. The clear oily product was obtained by removing 
the solvent by vacuum. (100% yield). 
 




Benzyl protected dopamine (1.43 g) was reacted with 0.43 g succinic anhydride in 6 mL 
pyridine and stirred at room temperature for 5 hours. Co-evaporation with toluene (toluene 5×5 
ml) was done to remove the solvent.  The white solid was washed with CH2Cl2 for 3 times and 
was drydried in vacuum, 1.4 g of the product was obtained. (89% yield). 
 





Benzyl protected dopamine-based carboxylic acid (0.964 g) and 0.426g EDC was and 
stirred in 100 mL CH2Cl2 at room temperature for 10 minutes. Next 0.433 g tetraethylene glycol 
was added followed by 5 mg DMAP and was stirring for 12 hours at room temperature. The 
organic phase was washed with 10% H3PO4 solution (3×10 mL), water (3×10 mL) and brine (10 
mL) and was dried with anhydrous MgSO4. The solvent was removed by vacuum. A weight of 
0.77g of the product was purified by column chromatography. The solvent system used was 1:1 
acetone:methylene chloride. (79% yield). 
 




Benzyl protected dopamine tetraethylene glycol (0.34 g) was dissolved in 50 mL 
methanol and was reacted with Pd/C (77 mg) under N2. Next 1 atm. H2 was applied and the 
mixture was stirred for 24 hours at room temperature. The catalyst was removed by filtering 
through a short pad of celite and the solvent was removed by vacuum. A weight of 0.23 g of 




2.6.3 Measuring the Heat Generation of Fe/Fe3O4 Nanoparticles by an alternating 
magnetic field 
For the measurement of the heating effect, an induction heater (Superior Induction 
Company, Pasadena, CA) was used. The heater is one inch in diameter and is a copper coil, with 
four turns, and is continuously cooled with cold water. The heater was operated with 5 kA/m 
field amplitude and 366 kHz frequency. The Fe/Fe3O4 nanoparticles were dispersed in water, and 
were subjected to the alternating magnetic field for 5 min. The temperature change was 
measured by a fiber optic probe (Neoptix, Quebec, Canada). 
2.6.4 Loading Mo/Ma with Nanoparticles and Determination of Iron Loading 
Concentration 
To determine the optimal concentration for nanoparticle loading, Mo/Ma were plated in 24 well 
plates and allowed to come to 70% confluency.  Medium was removed from the cells and fresh 
medium was added containing from 0 to 200 µg/mL iron from the nanoparticles.  Sixteen hours 
later the medium was removed, the cells were washed with PBS, and fresh medium was added.  
Loading confirmation and concentration were obtained by lifting the cells and running a 
ferrozine assay for iron content. The percent of cells loaded was measured using flow cytometry.  
Cytotoxicity was measured using the MTT assay (Flow Chart 1).   
For injections, Mo/Ma were cultured to 70% confluency in T75 flasks.  Sixteen hours 
before using the cells, cells for groups 3 and 5 (see below) were given nanoparticles consisting of 
373g (37.3g/mL) of iron added to the media in 100 L of PBS and mixed well.   At the same 
time, cells for groups 1, 2, and 4 were given 100 L of PBS.  The next morning, the medium was 
removed, the cells were washed with PBS, and fresh medium was added.  The cells were lifted 
by scraping and counted in a hemocytometer.  The correct cell density was attained by spinning 
the cells in 15 mL conical tubes at 1000 RPM for 5 minutes and resuspending in the correct 






Flow Chart 1:- Loading Mo/Ma with Nanoparticles and Determination of Iron Loading 
Concentration. 
 
2.6.5 Ferrozine Assay 
To determine the iron content of the nanoparticle solutions and the nanoparticle loaded 
cells, a ferrozine assay for iron was carried out.  Ferrozine reagent was prepared by dissolving 
9.7g ammonium acetate and 8.8g of ascorbic acid in 10 mL of water.  80mg of ferrozine and 
80mg of neocuprine were added to the solution and water was added to bring the total volume to 
25 mL.  The sample to be measured (either cell suspension or nanoparticle solution) was diluted 
to appropriate concentrations in deionized water.  For cell suspension samples, the cells were 
counted on a hemocytometer using trypan blue before dilution.  2 mL of the diluted sample was 
then placed in a test tube and 0.5 mL of 1.2 M HCl and 0.2 mL of 2M ascorbic acid was added.  
The sample was then vortexed and incubated at 70°C for 1 hour.  0.2 mL of the ferrozine reagent 
was then added to the test tube and the sample was incubated at room temperature for 30 min.   
A standard curve was also prepared with 0, 0.1, 0.2, 0.5, 1, 2, and 5 g/mL iron and treated in the 




samples was measured (Flow Chart 2).  The ABS562 versus iron concentration was plotted for the 
standard curve and the sample concentration was determined. 
 
 
Flow Chart 2:- Determining Iron Content by Ferrozine Assay. 
 
 
2.6.6 Flow Cytometry 
To find the percent of MNP loaded Mo/Ma, cells were treated with nanoparticles 
consisting of 5,10,15,20,or 25 µg/mL Fe.  The cells were incubated overnight and were washed 
twice with 1x PBS and analyzed by flow cytometry (Guava Easycyte Plus System, Millipore 
Corporation, MA).  Side scatter was measured and was used as a marker for nanoparticles; cells 
with increased side scatter compared to control cells were counted as MNP loaded cells. 
Experiment was conducted in triplicate and 10,000 cells were analyzed for each replicate. Data 






2.6.7 MTT Assay 
Thiazolyl blue was dissolved in PBS at 5 mg/mL to give the reagent solution.  MTT 
buffer solution was prepared as 10% (w/v) sodium dodecylsulfate and 0.1 M HCl in water.  To 
assay cell viability the reagent solution was added 1:10 to the cell medium and the cells were 
placed back into the incubator.  After four hours, the MTT buffer solution was added 1:1 to the 
medium and the plates were placed back into the incubator overnight.  After incubating, the 
absorbance at 550 nm and 690 nm was recorded.  The quantity ABS550 – ABS690 was calculated, 
and the control value was scaled to 100% cell viability. 
 
2.6.8 Tumor Homing  
To test the homing ability of Mo/Ma cells on Pan02 tumors, 7x10
5
 Pan02 cells were 
injected i.p. to two mice on day 0.  On day 4, 1x10
6
 PKH26 red fluorescent dye labeled Mo/Ma 
cells were injected i.p. (manufacturer’s instructions were followed for PKH26 labeling). Mice 
were euthanized on day 7 and 10, and tissues (mesentery/tumor, kidney, liver, spleen, lung) 
collected and fixed in buffered neutral formalin. Twenty-four hours after fixation, tissues were 
incubated in sucrose gradient and snap frozen. 5-8 micron sections were made and stained with 
Hoechst for nuclear counter-staining; serial sections were stained with hematoxylin and eosin 
(H&E). 
To verify that Mo/Ma cells were in Pan02 tumors, 7x10
5
 Pan02-fluc cells (which express 
firefly luciferase intracellularly) were injected i.p. to five mice on day 0.  On day 13, 1x10
6
 
Hoescht labeled Mo/Ma cells were loaded with MNP and were injected i.p.  Mice were 
euthanized on day 17 and tissues were snap frozen.  5-8 micron sections were made and stained 
with rabbit -firefly luciferase antibody and DyLite649 conjugated sheep -rabbit Igg antibody.   
 
2.6.9 Magnetic Heating Apparatus to generate AMF 
The AMF was generated by a converted 10 kW commercial inductive heater. In these 
experiments, only 1.5 kW power was used to produce 145 kHz sinusoidal alternating magnetic 
field in a copper coil. The magnetic field intensity has been calculated to be approximately 0.05 




heating effects from the resistive loss. The diameter of the coil was chosen to facilitate the 
complete inclusion of mice studies in the experiments including a perforated plastic tube. . 
 
2.6.10 Intratumoral Nanoparticle Heat Generation 
Six C57BL/6 mice (11 weeks old) were injected with 700,000 Pan02 cells in 100 L PBS 
subcutaneously.  To create a model for intratumoral heat generation by the loaded Mo/Ma, 21 
days later, when tumors were palpable, 1,000,000 Mo/Ma loaded with nanoparticles were 
injected in 10 L PBS intratumorally to three of the mice.  The other three mice received 
1,000,000 unloaded Mo/Ma in 10 L PBS intratumorally.  After injections, the mice were 
euthanized and the tumors were removed.  The temperature of the tumors was recorded using an 
infrared camera.  The tumors were then exposed to AMF for 15 min and the temperature of the 
tumors was again measured using the infrared camera.  The difference in temperature before and 















2.6.11 In Vivo Experiment 
C57BL/6 mice (11 weeks old) were injected with 700,000 Pan02 cells in 100 L PBS 
intraperitoneally (i.p.) on day 0 to generate a murine model of disseminated pancreatic cancer.  
These mice were then randomly divided into five groups as follows: (1) tumor control; (2) 
Mo/Ma control; (3) nanoparticle control; (4) AMF control; and (5) AMF treatment.   
On day 5, 2,000,000 Mo/Ma loaded with the nanoparticles were injected in 100 L PBS i.p. to 
groups 3 (nanoparticle control) and 5 (AMF treatment).  Groups 2 (Mo/Ma control) and 4 (AMF 
control) also received 2,000,000 Mo/Ma, which were not loaded.  Group 1 (tumor control) 
received 100 L PBS i.p.  This procedure was repeated on days 9 and 13. On day 8, mice from 
groups 4 (AMF control) and 5 (AMF treatment) were anesthetized with isofluorane and exposed 
to an AMF for 20 minutes.  This procedure was repeated on days 12 and 16 (Flow Chart 4) 
(Appendix A Figure A.9).   
After three rounds of treatments, the mice were closely observed and allowed to continue 
until they displayed signs of clinical symptoms of cancer, at which point they were euthanized 
using CO2, and the tumors were collected and weighed.   
 




2.6.12 Duration to Clinical Symptoms 
The measured outcome for this study was mouse survival.  To minimize potential pain 
and distress of the mice, however, a system was developed that allowed the euthanasia of the 
mice shortly before they died.  The mice were scored numerically 1 - 5 based on the body 
condition of the mice (primarily the spine and dorsal pelvic bone prominence) with a score of 3 
indicative of a healthy mouse.  This initial score was then modified by the presence of extreme 
lethargy, dehydration, ataxia, head tilt, severe hunching, limb dragging, severe raised hair, 
Harderian gland secretions, ascites, labored breathing, or bloody tail.  If pronounced, these 
symptoms led to a subtraction of 1 point from the BCS score while mild cases led to the addition 
of a ‘minus symbol‘ to the score (e.g. 3-).  The mice were scored by this system every 12 hours 
and any mouse that scored a 2 or less was euthanized and the day/time was recorded.  The 
euthanasia day/time data were then treated like survival data and modeled using Kaplan-Meier 






2.7.1 1H NMR data of the Compounds 
2.7.1.1 Boc-protected Dopamine 
1
H NMR (DMSO-d6) δ: 1.73 (s, 9H); 2.48 (t, 2H); 3.02 (q, 2H); 6.40 (d, 1H); 6.54 (s, 
1H); 6.61 (d, 1H); 6.83 (t, 1H); 6.85 (s, 1H); 6.76 (s, 1H). (Appendix B Figure B.74).   
2.7.1.2 Benzyl-protected Boc-dopamine 
1
H NMR (CDCl3) δ: 1.45 (s, 9H); 2.70 (t, 2H); 3.31 (q, 2H); 4.49 (s, 1H); 5.15 (d, 4H); 
6.71 (d, 1H); 6.80 (s, 1H); 6.88 (d, 1H); 7.32 (t, 2H); 7.37 (t, 4H); 7.45 (d, 4H). (Appendix B 
Figure B.75).   
2.7.1.3 Benzyl-protected dopamine 
1
H NMR (CDCl3) δ: 2.79 (t, 2H); 3.08 (m, 2H); 5.11 (s, 4H); 6.68 (d, 1H); 6.75 (s, 1H); 
6.90 (d, 1H); 7.32 (t, 2H); 7.35 (t, 4H); 7.42 (d, 4H). (Appendix B Figure B.76).   
2.7.1.4 Succinic anhydride coupled Benzyl-protected dopamine 
1
H NMR (DMSO-d6) δ: 2.29 (t, 2H); 2.42 (t, 2H); 2.60 (t, 2H); 3.21 (q, 2H); 5.09 (d, 
4H); 6.71 (d, 1H); 6.94 (s, 1H); 6.96 (d, 1H); 7.32 (t, 2H); 7.38 (d, 4H); 7.45 (t, 4H); 7.90 (t, 1H); 
12.08 (s, 1H). (Appendix B Figure B.77).   
2.7.1.5  Tetraethylene glycol coupled Benzyl-protected dopamine 
1
H NMR (CDCl3) δ: 2.39 (t, 2H); 2.57 (t, 1H); 2.70 (q, 4H); 3.44 (q, 2H); 3.60 (t, 2H); 
3.65 (broad 12H); 4.24 (t, 2H); 5.15 (d, 4H); 5.74 (t, 1H); 6.71 (d, 1H); 6.81 (s, 1H); 6.89 (d, 
1H); 7.31 (t, 2H); 7.37 (t, 4H); 7.46 (d, 4H). (Appendix B Figure B.78).   
2.7.1.6 Tetraethylene glycol coupled dopamine 
1
H NMR (DMSO-d6) δ: 2.33 (t, 2H); 2.48 (q, 2H); 3.15 (broad multiplet, 4H); 3.41 (t, 
2H); 3.49 (t, 2H); 3.51 (broad multiplet, 8H); 3.59 (t, 2H); 4.11 (t, 2H); 6.41 (d, 1H); 6.55 (s, 




2.7.2 Measuring the Heat Generation of Fe/Fe3O4 Nanoparticles by an alternating 
magnetic field 
More than 30 °C temperature increase was achieved when exposing a dispersion of 2.0 
mg nanoparticles in 2.0 mL of water to the alternating magnetic field for five minutes.The 
specific absorption rate (SAR) is calculated to be 522 ± 40 W/g. 
2.7.3 Toxicity and Loading of Nanoparticles  
   The nanoparticles did not show any toxicity at concentrations less than 100 g/mL Fe, 
although some slight toxicity was shown at 100 and 200 g/mL Fe (Appendix B Figure B.80 A).  
Mo/Ma took up the nanoparticles in a manner proportional to the iron concentration (Appendix B 
Figure B.80 B). The percentage of cells containing nanoparticles (defined as cells that exhibit 
increased side scatter after loading) also increased in a manner proportional to the iron 
concentration (Appendix B Figure B.80 C).  Based on these results, to prevent undesired toxicity 
while maximizing the amount of iron loaded, nanoparticles were loaded at 37.5 g/mL Fe for the 
in vivo experiment.  To determine the exact amount of iron loaded in the cells for the in vivo 
experiment, when Mo/Ma were lifted for the in vivo experiment, excess cells were collected and 
iron content was measured using the ferrozine assay.  The iron content of Mo/Ma injected was 
2.12 +/- 0.37 pg Fe/cell or 4.25 +/- 0.74 g Fe/2,000,000 cells.  
  
2.7.4 Tumor Homing Studies 
To determine if monocyte-like cells would home to Pan02 tumors, two mice bearing i.p. 
Pan02 tumors were injected i.p. with PKH26 labeled Mo/Ma.  Three days after injection, the first 
mouse was euthanized.  Tissue imaging showed that the monocyte-like cells effectively homed 
to the tumor, but did not infiltrate other organs, including the pancreas, spleen, liver, and kidney 
(Appendix B Figure B 81). At six days, the second mouse was sacrificed and tissue imaging 
showed again that the monocyte-like cells penetrated tumor tissue but not healthy tissue 
(Appendix B Figure B 81).   
H&E staining of serial sections demonstrate that the tissue that the Mo/Ma home to is 
highly disorganized, indicative of tumor tissue (Appendix B Figure B.82 A,B). To further verify 




expressing firefly luciferase were injected i.p. with Hoechst labeled Mo/Ma which were loaded 
with MNP.  Four days after injection, the mice were euthanized.  Antibody staining for firefly 
luciferase demonstrated that the Mo/Ma were in tumor tissue (Appendix B Figure B.82 C). 
 
2.7.5 Nanoparticle Heating of Tumors  
To verify that the cell-delivered nanoparticles could cause significant heating of the 
tumor, a subcutaneous Pan02 model was generated.  (The subcutaneous model was used to give 
more accessible tumors for measurement purposes).  The temperature change caused by AMF 
induced hyperthermia using the nanoparticle loaded Mo/Ma was 4.0+/-0.7°C after 15 min of 
AMF exposure, or moderate hyperthermia.  As a comparison, the temperature change using the 
unloaded Mo/Ma was 1.0+/-0.5°C (Appendix B Figure B.83, p value = 0.0056).   
 
2.7.6 Mouse Survival 
To determine the effectiveness of the treatment, Pan02 tumors were given i.p. to 
C57BL/6 mice and the mice were treated as described in the methods section. The euthanasia 
data were collected and modeled using Kaplan-Meier survival statistics.  The data are reported as 
days subsequent to tumor injection (day 0) (Appendix B Figure B.84). The Kaplan-Meier test 
showed that the survival curves were significantly different (p<0.005).  All of the mice from the 
tumor control group were euthanized due to clinical symptoms (hereafter referred to as 
‘succumbed’) by day 23.  Similarly all of the Mo/Ma control mice succumbed by day 25, all of 
the nanoparticle control mice succumbed by day 26 and all of the AMF control mice succumbed 
by day 25.  Modeling with Kaplan-Meier statistics showed no significant difference between any 
of these groups.  The AMF treatment mice survived substantially longer, with mice lasting until 
33.5 days.  The survival of the AMF treatment group was shown to be significant against all 
control groups (p<0.005 for all comparisons).  The average increase in survival versus tumor 
control for the nanoparticle treatment group was 7 days, a 31% increase in life expectancy post 






Here we have shown for the first time that tumor-homing cells can specifically deliver 
MNP for AMF therapy, and this treatment can significantly prolong the lives of mice bearing 
deep and disseminated intraperitoneal pancreatic tumors.  Core/shell iron/iron oxide MNP were 
synthesized that are superparamagnetic. Clusters of these nanoparticles are ferromagnetic. These 
MNP were loaded into Mo/Ma cells, which we demonstrated to be tumor homing cells.  The 
Mo/Ma cells were injected i.p. into tumor bearing mice and trafficked specifically to the tumor.  
Three days later, the mice were exposed to AMF, which caused the nanoparticles to generate 
heat, leading to localized hyperthermia. 
We found that the mouse monocytes homed effectively to the pancreatic tumors after i.p. 
administration.  This is not surprising because monocytes and/or macrophages are often found as 
tumor-associated cells.   Rat monocytes were shown to efficiently invade rat glioma spheroids in 
vitro, and peritoneal macrophages specifically migrated to rat gliomas after intravenous or 
intracarotid administration.
34, 35
 Interestingly, in this case, the mouse monocytes physically 
migrated only to the tumors within the peritoneal cavity, while normal tissues did not contain 
monocytes. 
Classically, hyperthermia kills tumor tissue by heating proteins and other 
macromolecules to the point of denaturing faster than the cell can renature them.  Since the 
system demonstrated here was substantially effective with only 4 g of iron injected into the 
mouse per treatment cycle, other mechanisms of action may be present.  The nanoparticle control 
group demonstrates that the nanoparticles themselves do not have any treatment value; similarly, 
the AMF control group demonstrates that AMF treatment does not have any stand-alone value.  
The Mo/Ma control group demonstrates that the Mo/Ma neither increase nor decrease tumor 
growth.  Thus, AMF activation of the MNP is primarily responsible for the effect.  Low grade 
hyperthermia has been shown to recruit various immune cells including dendritic cells, natural 
killer (NK) cells, neutrophils, and cytotoxic T cells.
55-62
 Although future studies need to be done, 
this or another similar mechanism may have greatly increased the effectiveness of the treatment 
and could explain why such a low dose of MNP can effect such a large survival advantage.   
We have described the development of a localized hyperthermia treatment using tumor-




Figure B.85). The system we describe here holds potential for further development as a specific 
delivery method for MNP-generated localized hyperthermia for targeted therapy of pancreatic 
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Figure A.1:- Synthetic scheme of the thiosemicarbazone iron chelator,  

















Figure A.3:- Preparation of core/shell Fe/Fe3O4 magnetic nanoparticles (MNPs). 
 






Figure A.5:- Coupling the thiosemicarbazone iron chelator to the free dopamine on the Fe/Fe3O4 
magnetic nanoparticles. 
Figure A.6:- Division of 96-well plate for MTT assay, for different concentrations of the 




Figure A.7:- Division of the 24-well plate for Prussian blue staining to determine loading of the 
nanosystems into 4T1 cell line. 
Figure A.8:- Nanoparticle synthesis.  
 A. Core/shell iron/iron oxide nanoparticles were synthesized and then coated in a 
dopamine based stealth ligand.  B, C, D. (This work has already been published in; International 






Figure A.9:- Treatment cycle for the in vivo study. 
(This work has already been published in; International Journal of Nanomedicine ,2012, 











HNMR of Hydrazinecarbodithioic acid methylester. 
1
H NMR (CDCl3-d, δ ppm) 2.66 (s, 3H, CH3), 4.15(s, 2H, NH3
+
 (protonated nitrogen) D2O 
exchangeable) 4.66 (s, 2H, NH2, D2O exchangeable), 8.11 (s, H, NH2
+
CS (protonated nitrogen), 







HNMR of the D2O exchanged of Hydrazinecarbodithioic acid methylester. 
1
H NMR (CDCl3-d, δ ppm) 2.66 (s, 3H, CH3), 4.15(s, 2H, NH3
+
 (protonated nitrogen) D2O 
exchangeable) 4.66 (s, 2H, NH2, D2O exchangeable), 8.11 (s, H, NH2
+
CS (protonated nitrogen), 







HNMR of the thiosemicarbazone iron chelator,  
N´-(Di-pyridin-2yl-methylene)- hydrazinecarbodithioic acid methylester. 
1
H NMR (CDCl3, δ ppm) 2.67 (s, 3H, CH3); 7.52 (s, H, NH);  8.81 (d, H3), 8.62 (d, H8), 8.06 (d, 







HNMR of the aryl hydrogens of the thiosemicarbazone iron chelator, N´-(Di-
pyridin-2yl-methylene)- hydrazinecarbodithioic acid methylester. 
1
H NMR (CDCl3, δ ppm) 2.67 (s, 3H, CH3); 7.52 (s, H, NH);  8.81 (d, H3), 8.62 (d, H8), 8.06 (d, 






CNMR of the thiosemicarbazone iron chelator,  
N´-(Di-pyridin-2yl-methylene)- hydrazinecarbodithioic acid methylester. 
13
C NMR (CDCl3, δ ppm, J, Hz): 17.70 (CH3); 124.08 (C10), 124.46 (C5), 124.69 (C12), 127.56 
(C7), 137.33 (C6 & 11), 142.55 (C13), 148.30 (C8), 148.62 (C9), 151.31 (C4) of the Ar-C; 






Figure B.6:- HPLC of the CGKRK(D[KLAKLAKKLAKLAK])PLFAERL peptide sequence. 


















Figure B.9:- UV graph of Peptide-Dopamine-NP-Dopamine-Thiosemicarbazone (1:10) reaction.  
 
 































































































Figure B.22:- Zeta potential of Blank (distilled water). 
 
 
















Figure B.26:- Zeta potential of Peptide-Dopamine-NP-Dopamine-Thiosemicarbazone (1:5). 
 
 






Figure B.28:- Zeta potential of Peptide-Dopamine-NP-Dopamine-Thiosemicarbazone (5:1). 
 
 






Figure B.30:- FTIR of Peptide-Dopamine-NP. 
 






Figure B.32:- FTIR for Peptide-Dopamine-NP-Dopamine-Thiosemicarbazone 1:5. 
 
 





Figure B.34:- FTIR for Peptide-Dopamine-NP-Dopamine-Thiosemicarbazone 5:1. 
 





Figure B.36:- FTIR of Thiosemicarbazone-Dopamine-NP (1:10). 
 






Figure B.38:- FTIR of Thiosemicarbazone-Dopamine-NP (1:1). 
 






Figure B.40:- FTIR of Thiosemicarbazone-Dopamine-NP (10:1). 
 
 







Figure B.42:- Cell toxicity graph of Peptide-Dopamine- nanoparticle.  
 
 







Figure B.44:- Cell toxicity graph of Peptide-Dopamine-NP-Dopamine-Thiosemicarbazone (1:5).  
 





Figure B.46:- Cell toxicity graph of Peptide-Dopamine-NP-Dopamine-Thiosemicarbazone (5:1).  
 







Figure B.48:- Cell toxicity graph of Thiosemicarbazone-Dopamine-NP (1:10).  
 
 






Figure B.50:- Cell toxicity graph of Thiosemicarbazone-Dopamine-NP (1:1).  
 
 




























































































































Figure B.72:- Prussian blue staining of 4T1 cells incubated with 5µg Thiosemicarbazone-




Figure B.73:- Prussian blue staining of 4T1 cells incubated with 10µg of Thiosemicarbazone-
































































Figure B.80:- Nanoparticle Loading.   
      Mo/Ma were cultured overnight in increasing concentrations of nanoparticles.  The next 
morning cells were washed and assayed. A. Toxicity of Nanoparticles:  Cells were assayed for 
viability using MTT.  B. Loading of Nanoparticles:  Cells were assayed for iron content using the 
ferrozine assay.  C. Percent of Cells Loaded: Cells were assayed for increased side scatter using 
flow cytometry.  Error bars are standard deviation. 
(This work has already been published in; International Journal of Nanomedicine ,2012, 












Figure B.81:- Mo/Ma Only Infiltrate Pan02 Tumors.  
 PKH26 labeled monocytes were injected i.p. into mice bearing i.p. Pan02 tumors.  A-F. 
Mice were euthanized three days after monocyte injection and organs were harvested and imaged 
for PKH26 (monocytes).  Representative images are shown. A. Tumor 10x; B. Tumor 40x; C. 
Pancreas; D. Kidney; E. Liver; F. Lung.  G-L.  Mice were euthanized six days after monocyte 
injection and organs were harvested and imaged for PKH26 (monocytes).   Representative 
images are shown. G. Tumor (note healthy pancreas at the top left); H. Tumor; I. Pancreas; J. 
Kidney; K. Liver; L. Lung. Blue is DAPI (nuclear counterstain), Red is PKH26 (monocytes).  
All scale bars are 100 m, objective is 20x unless otherwise specified. (This work has already 






Figure B.82:- Mo/Ma Infiltrate Pan02 Tumors.  
 A,B. Mo/Ma loaded with PKH26 were injected into mice bearing i.p. Pan02 tumors.  Six days 
later mice were euthanized and tumors were harvested.  A. Dapi counterstained section shows 
Mo/Ma labeled with PKH26 in tumor.  Blue = Dapi, Red = PKH26 (Mo/Ma).  B. H&E staining 
of serial sections shows irregular morphology demonstrating that the targeted area is a tumor. 
Scale bars = 100 m.  C. Mo/Ma loaded with Dapi were injected into mice bearing Pan02(fluc) 
tumors.  Five days later mice were euthanized and tumors were harvested.  Sections were stained 
with rabbit anti-firefly luciferase and DyLite649-goat anti rabbit.  Immunohistochemistry 
verifies that the Mo/Ma infiltrate pancreatic tumors.  Blue = Dapi (Mo/Ma), Red = DyLite 649 
(Pan02 cells).  Scale bar = 100 m. 
(This work has already been published in; International Journal of Nanomedicine ,2012, 







Figure B.83:- Heat generation by nanoparticle loaded Mo/Ma.   
(This work has already been published in; International Journal of Nanomedicine ,2012, 
Vol 7, 297–306.) 
Figure B.84:- Duration to Clinical Symptoms (‘Survival’).   
Mice were treated and monitored as described.  Mice were euthanized when they 
displayed clinical signs of cancer and the day/time was recorded (n=5 or 6 for each group). 
p<0.005 for AMF treatment versus all other groups. (This work has already been published in; 








Figure B.85:- Model of the demonstrated system.   
First, nanoparticles were loaded into Mo/Ma by coculture.  The Mo/Ma were then injected i.p. 
into mice bearing i.p. Pan02 tumors and they specifically homed to the tumors.  Three days after 
injecting the cells, the mice were exposed to AMF, which caused the nanoparticles to generate 
heat, leading to hyperthermia. 
(This work has already been published in; International Journal of Nanomedicine ,2012, 













Appendix C - Previous Experimental Attempts 
C.1 Experimental Procedure 1 
We first tried to synthesize the thiosemicarbazone analogue coupled to 4-(hydrazine 
carbothioamido) butonic acid. The next step was to couple the peptide sequence to the carboxylic 
acid of the 4-(hydrazine carbothioamido) butonic acid coupled thiosemicarbazone analogue. 
Next coupling of the dopamine to peptide and coating the Fe/Fe3O4 nanoparticle was to be done. 
The nanoplatform synthesis is shown in Scheme 1 and 2. 
In this procedure the first step was to synthesize 4-(hydrazine carbothioamido) butonic 
acid by reacting 4-aminobutyric acid with carbondisulfide and hydrazine hydrate as shown in 
scheme 1.
1
 The reaction was carried out by first dissolving 4-aminobutyric acid (1 eq) in cold 
ethanol   (0-5
o
C). To this solution potassium hydroxide (1 eq) and carbon disulfide (2eq) was 
added and was stirred for 1 hr. Next hydrazine hydrate (1 eq) was added and was reacted at 50
0
C 
for 2 hours. However, as stated in reference 1, we did not obtain any precipitate as a product. We 
took an aliquot of the clear reaction solution, removed the solvent by means of rotary 
evaporation, and took a 
1
H-NMR to discern if any 4-(hydrazine carbithioamido) butonic acid was 
formed.  
1
H NMR (DMSO-d6, δ ppm) 1.82 (m, 2H, CH2 β to COOH), 2.03 (s, 2H, NHCSNH, 
D2O exchangeable), 2.23 (t, 2H, CH2 α to COOH), 3.36 (t, 2H, CH2 γ to COOH), 4.34 (s, 2H, 
NH2, D2O exchangeable), 12.24 (s, 1H, OH of COOH, D2O exchangeable) as stated in reference 
1 (Figure C.1).  
According to 
1
H NMR some 4-(hydrazine carbothioamido) butonic acid had formed  
(Figure C.2). Several attempts were carried out to purify the product 4-(hydrazine 
carbothioamido) butonic acid, however purification was not successful and were not able to 

































H NMR of the 4-(hydrazine carbothioamido) butonic acid reaction mixture. 
 
C.2 Experimental procedure 2 
Next, we reacted t-butyl protected glycine with the thiosemicarbazone analogue 
(synthesized as in 1.7.1), as shown in Scheme 3.
1
 And next to be continued from the second step  
as in the Scheme 1 to 2. The reaction was performed with different ratios of protected glycine (1 
eq, 1.25 eq), at different temperatures (room temperature and 50
o
C) and at reaction different 
times(2 hrs, 1-6 days). A spot on a TLC plate was seen in the reaction performed at r.t for 6 days 
with 1.25 eq of protected glycine. The TLC was carried out on silica plates with 1:9 solvent ratio 
of ethanol: methylene chloride (Figure C.3). We took an aliquot of the clear reaction solution, 
removed the solvent by means of rotary evaporation, and took a 
1
H-NMR to discern if any 
product was formed. But the 
1
H-NMR (Figure C.5) turned out to be as same as the 
thiosemicarbazone analogue as seen in Figure B.3. No product was formed therefore a 


















Figure C.4:- Predicted 
1







H-NMR of the reaction mixture of thiosemicarbazone coupled with t-butyl 








The reaction was also carried out in DCM with coupling reagents EDC (1.2 eq), DMAP 
(1 eq) and was refluxed at 80
o
C and was monitored with TLC, presence of a product was 
detected (Figure C.6). The reaction mixture was washed with water to remove the coupling 
reagents. The organic layer removed by means of rotary evaporation, and a 
1
H-NMR was taken 
to discern if any product was formed. From the 
1
H-NMR (Figure C.7 crude) presence of 
coupling reagents were still observed therefore purification of the product was attempted through 
a silica column with 1:9 solvent ratio of ethanol: methylene chloride as the solvent. However 
from the 
1
H-NMR of the purification fractions it was observed that the product was not able to 
be completely purified (Figure C. 8-14). Therefore a yield for the pure compound was not able to 
be obtained. 
 
Figure C.6:- TLC of the EDC coupling reaction method for thiosemicarbazone coupled with t-









H-NMR of  thiosemicarbazone coupled with t-butyl protected glycine using the 







H-NMR of fraction 1 of  thiosemicarbazone coupled with t-butyl protected glycine 











H-NMR of fractions 2,3,4 of  thiosemicarbazone coupled with t-butyl protected 






H-NMR of fraction 5 of  thiosemicarbazone coupled with t-butyl protected 









H-NMR of fraction 6 of  thiosemicarbazone coupled with t-butyl protected 








H-NMR of fraction 7 and 8 of  thiosemicarbazone coupled with t-butyl protected 










H-NMR of fractions 9 and 10 of  thiosemicarbazone coupled with t-butyl 






H-NMR of fraction 11 of  thiosemicarbazone coupled with t-butyl protected 





C.3 Experimental procedure 3 
Next, we reacted glycine with the hydrazine carbothio methyl ester (synthesized as in 
1.7.1). This was done by dissolving potassium hydroxide (2 eq) in hot ethanol (70
o
C) and then 
glycine (1 eq) was added. The solvent was removed by means of rotary evaporation. A white 
product was remaining. This product was added to a solution of hydrazine carbothio methyl ester 
(1 eq) and refluxed at 80
o
C for 48 hrs. After 2 hrs di -2-pyridylketone (1 eq) was added and 
further refluxed for 48 hrs (Scheme 4).
1,2
  The solution was acidified to convert the salt product 
(if any formed) to the organic form. TLC was carried out on silica plates with a 1:9 solvent ratio 
of ethanol: methylene chloride (Figure C.15). The crude 
1
H-NMR is shown in figure C.17. 
Purification of the product was attempted on a silica column and the 
1
H-NMR’s of the fractions 
are shown in figures C.18-21. The first 2 fractions were eluted using ethyl acetate 1:2 hexane. 
The other fraction were eluted with 1:20 solvent ratio of ethanol: methylene chloride. However, 
we were not able to completely purify the reaction product, therefore a yield was not able to be 
calculated. This may be due to reaction on the column or due to the formation of numerous by-















Figure C.16:- Predicted 
1











































H-NMR of fraction 8 of glycine coupled thiosemicarbazone reaction. 
 
C.4 Experimental procedure 4 
The next attempt was to react the thiosemicarbazone analogue (1 eq) (synthesized as in 
1.7.1) with 1,1'-carbonyldiimidazole (CDI) (1.2 eq) in DMF under argon for 2 hrs. In step 2, 
glycine was added to the reaction mixture and the reaction was monitored by TLC for 2 days. 
Since no product formed, the reaction mixture was refluxed at 120 
o
C overnight (scheme 5).  
Methylene chloride was added and DMF was removed by washing with water and extracting the 
compound into methylene chloride. The organic layer was washed three times with saturated 
aqueous sodium chloride. Several spots on the TLC were seen when developed with 1:10 solvent 
ratio of ethanol: methylene chloride (Figure C. 22) (crude 
1
H-NMR Figure C.23). Purification of 
the product was attempted on a silica column with with 1:10 solvent ratio of ethanol: methylene 
chloride. However the fraction obtained were shown to be not pure as seen in the 
1
H-NMR’s 
(Figures C.24-30) of the column fractions. Therefore percentage yield of the pure product could 
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